Page last updated: 2024-10-24

caffeine and Apnea

caffeine has been researched along with Apnea in 302 studies

Apnea: A transient absence of spontaneous respiration.

Research Excerpts

ExcerptRelevanceReference
"In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared."9.51Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022)
" Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation."9.41Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023)
"The purpose of this meta-analysis is to investigate the effect of prophylactic caffeine use in the treatment of apnea and other clinical outcomes in very low birth weight infants."9.41Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Teng, P; Wang, A; Zhang, Y; Zhao, S, 2023)
"Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants."9.41Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023)
"To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants."9.41Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023)
" Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines."9.41Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023)
"There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy."9.41Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021)
"Caffeine citrate is used to prevent apnea in premature infants and help in extubation of invasive ventilation, but the optimal dose remains undetermined."9.34Caffeine citrate maintenance doses effect on extubation and apnea postventilation in preterm infants. ( Chen, P; Huang, L; Wan, L, 2020)
"To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants."9.34[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020)
"Preterm infants with apnea who were born at less than 32 weeks of gestational age and birth weight ≤1500 g were randomly divided into caffeine citrate prevention group and caffeine citrate treatment group."9.34Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea. ( Gao, Z; Han, D; Kou, C; Li, Z; Liu, Z; Wu, W; Zhang, Y, 2020)
"To study the clinical effect and safety of different maintenance doses of caffeine citrate in the treatment of apnea in very low birth weight preterm infants."9.30[Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial]. ( Lyu, Y; Wang, LF; Yang, ZY; Zhang, HT; Zhang, X, 2019)
"Caffeine is effective in the treatment of apnea of prematurity."9.27Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018)
"Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight."9.24Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017)
"To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity."9.24Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017)
"240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015."9.24Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017)
" Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD."9.22Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022)
"Apnea of prematurity (AOP) is one of the common diseases in preterm infants."9.22[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022)
"Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity."9.22Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022)
"To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge."9.22Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016)
"To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants."9.22[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016)
"To investigate the effect of caffeine citrate treatment on early pulmonary function in preterm infants with apnea."9.22[Effect of caffeine citrate on early pulmonary function in preterm infants with apnea]. ( Huang, JH; Wen, XH; Wu, WY; Yu, M; Zhang, XZ; Zhu, R, 2016)
"It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants."9.22Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016)
"To evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis."9.22Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial. ( Ahmed, W; Alansari, K; Davidson, BL; El Tatawy, LA; Khalafalla, H; Toaimah, FH, 2016)
"• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years."9.20High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015)
"Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication."9.19The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014)
"To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD)."9.19Reduction in developmental coordination disorder with neonatal caffeine therapy. ( Anderson, PJ; Davis, PG; Doyle, LW; Grunau, RE; Herlenius, E; Moddemann, D; O'Brien, K; Roberts, R; Sankaran, K; Schmidt, B, 2014)
"Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system."9.19Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014)
"3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004."9.16Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012)
"To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring."9.14Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009)
"To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial."9.14Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010)
"The objective of this study was to develop a population model of the pharmacokinetics (PK) of caffeine after orogastric or intravenous administration to extremely premature neonates with apnea of prematurity who were to undergo extubation from ventilation."9.13Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. ( Charles, BG; Flenady, VJ; Gray, PH; Shearman, A; Steer, PA; Townsend, SR, 2008)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed."9.12Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed."9.12Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007)
"Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator."9.11Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005)
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0."9.09Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999)
"To evaluate the efficacy and safety of caffeine citrate for treatment of apnea of prematurity."9.09Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. ( Erenberg, A; Haack, DG; Hicks, GM; Leff, RD; Mosdell, KW; Wynne, BA, 2000)
" Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia."9.08Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995)
"Caffeine is a potentially useful alternative to theophylline for the treatment and prevention of apnea of prematurity because of its lower toxicity and longer terminal half-life."9.08Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. ( Charles, BG; Flenady, VJ; Lee, TC; Steer, PA, 1996)
"The study the population pharmacokinetics of caffeine after intravenous administration to premature infants with apnea."9.08Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. ( Charles, B; Flenady, V; Lee, TC; Shearman, A; Steer, P, 1997)
" Tracings were analyzed for evidence of apnea, periodic breathing, and/or bradycardia by a pulmonologist unaware of the drug given."9.06High-dose caffeine suppresses postoperative apnea in former preterm infants. ( Fink, R; Hannallah, RS; Hicks, JM; Ruttimann, UE; Welborn, LG, 1989)
"Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults."9.05Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020)
" The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs."9.05Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020)
"This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant."9.05The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981)
"The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants."9.05Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985)
"Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants."8.98Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018)
"The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline."8.95Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017)
"Caffeine is a methylxanthine that is widely used to treat apnea of prematurity (AOP)."8.95Caffeine for apnea of prematurity: Effects on the developing brain. ( Atik, A; Cheong, J; De Matteo, R; Doyle, LW; Harding, R; Kondos-Devcic, D; Tolcos, M, 2017)
"The respiratory stimulant caffeine is the most frequently used xanthine (theophylline or aminophylline) for the treatment of apnea in premature infants."8.91An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats. ( Bairam, A; Joseph, V; Mubayed, S; Uppari, N, 2015)
"Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g."8.90Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014)
" It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity."8.90Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014)
"Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems."8.87Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011)
"Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult."8.86[Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010)
"To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea."8.86Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010)
" The diagnosis of apnea of prematurity (AOP) is one of exclusion."8.82Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003)
"All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included."8.81Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001)
"Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates."8.81Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001)
"All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included."8.80Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants."8.80Current options in the management of apnea of prematurity. ( Bhatia, J, 2000)
"Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation."8.80Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000)
" Second, we recommend the use of intravenous caffeine base 10 mg/kg in all infants at risk for postoperative apnea following general anesthesia."8.79Anesthesia and apnea. Perioperative considerations in the former preterm infant. ( Greenspun, JC; Welborn, LG, 1994)
"Apnea of prematurity is one of the most common problems in the neonatal intensive care unit."8.79Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996)
"Caffeine and theophylline are effective in the treatment of apnea in the newborn infant."8.76Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979)
" Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age."8.31Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age. ( Akdere, SK; Atalah, YEY; Barış, HE; Boran, P; Eralp, EE; Gücüyener, K; Özdemir, H; Özek, E; Sabancı, M, 2023)
"Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity."8.12Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022)
"The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity."8.12The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022)
"Caffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity."8.02Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study. ( Gueta, I; Hanna, M; Loebstein, R; Rosen, C; Strauss, T; Taran, C; Yarden-Bilavsky, H, 2021)
"Apnea is commonly encountered in children with bronchiolitis."7.96Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit. ( Brossier, D; Denis, M; Faucon, C; Goyer, I; Heuzé, N; Jokic, M; Porcheret, F, 2020)
"Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity."7.96Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020)
" Methylxanthine is widely administered for the treatment of apnea of prematurity in many countries, and previous reports have clearly established that caffeine is effective for the treatment of apnea of prematurity."7.88[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants]. ( Kamimura, H; Nagasato, A; Nakamura, M, 2018)
"This study explored the feasibility effect and safety of the limb stimulation (LS) for the treatment of neonatal apnea (NAP)."7.88A pilot study of limb stimulation for the treatment of neonatal apnea. ( Dong, LB; Li, YF; Qiao, S; Zhang, Y, 2018)
"To study the clinical effect of early or late administration of caffeine citrate in the prevention and treatment of apnea in very low birth weight (VLBW) infants."7.88[Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants]. ( Chen, X; Cheng, R; Feng, Y; Mao, XN; Qiu, J; Zhao, L, 2018)
"Incidence fell from 74% diagnosed with apnea of prematurity at baseline to 49% diagnosed with CSCPE postimplementation (P<0."7.85Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management. ( Ahlers-Schmidt, CR; Bloom, BT; Engel, M; Powell, MB, 2017)
"Apnea of prematurity affects a small proportion but large absolute number of late preterm infants, with out-patient management variably utilized despite relative clinical equipoise and potential for improved cost-effectiveness."7.85Economics of Home Monitoring for Apnea in Late Preterm Infants. ( Amberson, M; Dukhovny, D; Freiberger, C; Montenegro, BL; Rhein, LM; Veit, L, 2017)
"Apnea of prematurity (AOP) is nearly universal among very preterm infants, but neither the apnea burden nor its clinical associations have been systematically studied in a large consecutive cohort."7.83Clinical associations of immature breathing in preterm infants: part 1-central apnea. ( Delos, J; Fairchild, K; Kattwinkel, J; Lake, D; Mohr, M; Moorman, JR; Paget-Brown, A; Tabacaru, C, 2016)
" Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords."7.83[Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016)
"Caffeine, standard treatment for apnea of prematurity, improves brainstem auditory processing."7.81Effects of caffeine treatment for apnea of prematurity on cortical speech-sound differentiation in preterm infants. ( Aschner, JL; Chan, J; Key, AP; Lambert, WE; Maitre, NL; Stark, AR, 2015)
"Apnea is nearly universal among very low birth weight (VLBW) infants, and the associated bradycardia and desaturation may have detrimental consequences."7.81Very long apnea events in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Kattwinkel, J; Lake, DE; Lee, H; Mennen, AC; Mohr, MA; Moorman, JR; Sinkin, RA; Vergales, BD, 2015)
"Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline."7.81Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015)
" We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity."7.80Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014)
"Apnea of prematurity, a common disorder, can severely compromise an infant's condition unless correctly diagnosed and treated."7.80Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost. ( Butler, TJ; Firestone, KS; Grow, JL; Kantak, AD, 2014)
"To investigate the clinical efficacy and safety of caffeine citrate and aminophylline in the treatment of primary apnea in premature infants."7.80[Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants]. ( Chen, DM; Wang, RQ; Xu, JL, 2014)
" Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis."7.79Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013)
"To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age."7.77Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011)
"The mechanisms underlying the therapeutic function of caffeine on apneas in preterm neonates are not well determined."7.76Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. ( Bairam, A; Joseph, V; Julien, CA, 2010)
"Caffeine is a common treatment for apnea of prematurity."7.75Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone. ( Bairam, A; Joseph, V; Kinkead, R; Lajeunesse, Y; Montandon, G, 2009)
"Caffeine is an adenosine receptor antagonist commonly used as a respiratory stimulant to treat neonatal apneas of premature newborn."7.73Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats. ( Bairam, A; Kinkead, R; Montandon, G, 2006)
"Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies."7.73[Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006)
"Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age."7.73[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006)
" This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea."7.71Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001)
"To report the occurrence of apnea and bradycardia in two former pre-term infants who received spinal anaesthesia without inhalational or intravenous anaesthetic agents during inguinal herniorrhaphy."7.70Apnea following spinal anaesthesia in two former pre-term infants. ( Burd, RS; Helikson, MA; Tobias, JD, 1998)
"A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea."7.70Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000)
"To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications."7.70Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000)
"Apnea of prematurity is a common problem in neonatal intensive care nurseries."7.68Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993)
"The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated."7.68Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992)
"The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea."7.68[Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991)
" Comparison of the groups using quantitative measures of apnea, bradycardia, and periodic breathing obtained from pneumogram analysis and the incidence of monitor alarms on bedside nursing records showed no significant differences."7.67Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication. ( Braun, RJ; Evans, MA; Kelly, DH; McCulloch, KM; Simms, PE, 1989)
"Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"."7.67[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987)
"This review provides an understanding of current problems related to apnea of infancy."7.67Infant apnea. ( Fox, WW; Spitzer, AR, 1986)
"To evaluate the relationship of antecedent maternal smoking and caffeine consumption habits on the occurrence of apnea in their offspring, rates for central and obstructive apnea were analyzed in a cohort of mother-infant pairs."7.67Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study. ( Bendell, D; Duke, JC; Mattice, CD; McCaffree, MA; Orr, WC; Toubas, PL, 1986)
" Because caffeine is a respiratory stimulant, its effect on breathing pattern was evaluated in 12 infants with infantile apnea."7.66Effect of caffeine on control of breathing in infantile apnea. ( Aranda, JV; Davis, J; Grondin, D; Trippenbach, T; Turmen, T; Watters, G; Zinman, R, 1983)
"The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea."7.66Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983)
" Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test."7.66Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982)
"Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea."7.66Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981)
"Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants."7.66Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979)
"The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule."7.66Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979)
"The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated."7.65Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977)
" The aims of this study were to develop and evaluate population pharmacokinetic (PPK) models of caffeine in preterm infants through comprehensive screening of covariates and then to propose model-informed precision dosing of caffeine for this population."5.72Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms. ( Chen, F; Cheng, R; Dai, HR; Ding, XS; Guo, HL; He, X; Hu, YH; Jiao, Z; Liu, Y; Lu, KY; Xu, J, 2022)
"Caffeine is commonly used to prevent or treat apnea in preterm neonates."5.51Effect of Prophylactic Caffeine on Noninvasive Respiratory Support in Preterm Neonates Weighing 1250-2000 g: A Randomized Controlled Trial. ( Armanian, AM; Feizi, A; Iranpour, R; Miladi, N, 2022)
"In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared."5.51Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022)
" Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation."5.41Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023)
"Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants."5.41Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023)
"To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants."5.41Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023)
" Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines."5.41Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023)
"There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy."5.41Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021)
"To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants."5.34[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020)
" There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0."5.34Early application of caffeine improves white matter development in very preterm infants. ( Liu, S; Liu, Y; Wang, X; Xu, F; Yang, L; Yuan, X; Zhang, R; Zhang, X; Zhu, C, 2020)
"Preterm infants with apnea who were born at less than 32 weeks of gestational age and birth weight ≤1500 g were randomly divided into caffeine citrate prevention group and caffeine citrate treatment group."5.34Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea. ( Gao, Z; Han, D; Kou, C; Li, Z; Liu, Z; Wu, W; Zhang, Y, 2020)
"The study was performed using information on echocardiography measurements from preterm neonates recruited for apnea of prematurity (75 of 240) and preventing extubation failure (113 of 156) studies."5.30Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups. ( Kamath, A; Lewis, LES; M, S; Nayak, K; Purkayastha, J, 2019)
"Caffeine is effective in the treatment of apnea of prematurity."5.27Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018)
"Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively."5.27Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985)
" The mean plasma half-live of theophylline was 22."5.26[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981)
"Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight."5.24Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017)
"To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity."5.24Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017)
"240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015."5.24Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017)
" Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD."5.22Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022)
"Apnea of prematurity is a developmental disorder affecting most extremely preterm infants."5.22Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant. ( Bancalari, E; Chavez, L, 2022)
"Apnea of prematurity (AOP) is one of the common diseases in preterm infants."5.22[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022)
"Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity."5.22Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022)
"To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge."5.22Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016)
"To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants."5.22[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016)
"To investigate the effect of caffeine citrate treatment on early pulmonary function in preterm infants with apnea."5.22[Effect of caffeine citrate on early pulmonary function in preterm infants with apnea]. ( Huang, JH; Wen, XH; Wu, WY; Yu, M; Zhang, XZ; Zhu, R, 2016)
"It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants."5.22Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016)
"To evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis."5.22Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial. ( Ahmed, W; Alansari, K; Davidson, BL; El Tatawy, LA; Khalafalla, H; Toaimah, FH, 2016)
"Early caffeine treatment can reduce the need for assisted ventilation in preterm infants with RDS, help with early extubation and ventilator weaning, reduce the oxygen time in the late stage, reduce the incidence of VAP, and prevent the development of apnea after extubation."5.22[Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome]. ( Duan, YH; Han, JT; Su, P; Wei, QZ; Zhang, X, 2016)
"• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years."5.20High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015)
"Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication."5.19The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014)
"To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD)."5.19Reduction in developmental coordination disorder with neonatal caffeine therapy. ( Anderson, PJ; Davis, PG; Doyle, LW; Grunau, RE; Herlenius, E; Moddemann, D; O'Brien, K; Roberts, R; Sankaran, K; Schmidt, B, 2014)
"Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system."5.19Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014)
"3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004."5.16Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012)
"To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring."5.14Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009)
"To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial."5.14Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed."5.12Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006)
"We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed."5.12Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007)
"Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator."5.11Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005)
"Monohydrated caffeine was the only respiratory xanthine available in our country to treat apnea of premature infant."5.10[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant]. ( Belkahia, C; Boukef-Larguèche, S; Chaouachi, S; Cherif, A; Klouz, A; Marrakchi, Z, 2003)
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0."5.09Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999)
"Preterm infants with a gestational age of <32 weeks and birth weight of <1,500 g were randomized to receive either caffeine or aminophylline treatment for apnea of prematurity."5.09Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. ( Bertini, G; Dani, C; Martelli, E; Reali, MF; Rubaltelli, FF; Tronchin, M; Wiechmann, L, 2000)
"Aminophylline and caffeine are commonly used for prophylaxis of apnea in premature infants."5.08Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. ( Brendstrup, L; Greisen, G; Larsen, PB; Lundstrøm, KE; Skov, L, 1995)
" Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia."5.08Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995)
" Tracings were analyzed for evidence of apnea, periodic breathing, and/or bradycardia by a pulmonologist unaware of the drug given."5.06High-dose caffeine suppresses postoperative apnea in former preterm infants. ( Fink, R; Hannallah, RS; Hicks, JM; Ruttimann, UE; Welborn, LG, 1989)
"Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults."5.05Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020)
" The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs."5.05Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020)
" In the large international Caffeine for Apnea of Prematurity trial, caffeine improved survival without neurodevelopmental disability at 18 months and demonstrated long term safety up to 11 years."5.05Neurodevelopmental outcomes after neonatal caffeine therapy. ( Grunau, RE; Synnes, A, 2020)
"Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment."5.05Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose? ( Patel, RM; Saroha, V, 2020)
"The Caffeine for Apnea of Prematurity (CAP) trial showed that caffeine was safe when used with standard dosing and provided both pulmonary and neurological benefits to preterm infants."5.05National and international guidelines for neonatal caffeine use: Are they evidenced-based? ( Eichenwald, EC, 2020)
"This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant."5.05The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981)
"The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants."5.05Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985)
" While robust evidence supports the use of standard doses of caffeine for apnea of prematurity or to facilitate successful extubation, much remains unknown regarding the boundaries of efficacy and safety for this common therapeutic agent."5.01Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. ( McPherson, C; Rostas, SE, 2019)
"Caffeine therapy for apnea of prematurity (AOP) remains one of the pillars of neonatal care, although more evidence to support dosing and timing of initiation and discontinuation are needed."4.98Caffeine controversies. ( Carlo, WA; Gentle, SJ; Travers, CP, 2018)
"Placebo-controlled trials have shown that caffeine is highly effective in treating apnoea of prematurity and reduces the risk of bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment (NDI)."4.98High versus standard dose caffeine for apnoea: a systematic review. ( Hutten, GJ; Miedema, M; Onland, W; van Kaam, AH; Vliegenthart, R, 2018)
"Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants."4.98Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018)
"Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants."4.98Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018)
" It is used for the prevention and treatment of apnea, although this has been associated with lower incidence of bronchopulmonary dysplasia (BPD) and patent ductus arteriosus as well as intact survival at 18-21 months of life."4.95Caffeine use in the neonatal intensive care unit. ( Abu-Shaweesh, JM; Martin, RJ, 2017)
"The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline."4.95Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017)
" Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life."4.93Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016)
" The benefits of methylxanthine-based therapies in the apnea of prematurity and their translational potential in pediatric affections of the respiratory tract are here presented."4.93The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. ( Franco, R; Martínez-Pinilla, E; Oñatibia-Astibia, A, 2016)
"Caffeine is one of the most commonly prescribed medications in preterm neonates and is widely used to treat or prevent apnea of prematurity."4.93The Role of Caffeine in Noninvasive Respiratory Support. ( Dobson, NR; Patel, RM, 2016)
"The respiratory stimulant caffeine is the most frequently used xanthine (theophylline or aminophylline) for the treatment of apnea in premature infants."4.91An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats. ( Bairam, A; Joseph, V; Mubayed, S; Uppari, N, 2015)
"The use of caffeine citrate for treatment of apnea in very low birth weight infants showed short-term and long-term benefits."4.91Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis. ( Chung, S; Chung, SH; Kim, KS; Kim, SN; Lim, G; Park, HW, 2015)
"Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g."4.90Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014)
" It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity."4.90Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014)
"Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems."4.87Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011)
"Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult."4.86[Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010)
"To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea."4.86Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010)
" This ubiquitous trimethylxanthine, pervasively used in the human diet and beverages, significantly impacts on major acute neonatal morbidities including apnea of prematurity, bronchopulmonary dysplasia, patent ductus arteriousus with or without surgical ligation and post-operative apnea."4.86Caffeine impact on neonatal morbidities. ( Aranda, JV; Beharry, K; Davis, J; Natarajan, G; Valencia, GB, 2010)
" The diagnosis of apnea of prematurity (AOP) is one of exclusion."4.82Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003)
"All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included."4.81Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001)
"Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates."4.81Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001)
" Caffeine is used to treat apnea of the newborn because of its low toxicity."4.80Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. ( Kotagal, U; Pesce, AJ; Rashkin, M, 1998)
"All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included."4.80Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000)
"Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants."4.80Current options in the management of apnea of prematurity. ( Bhatia, J, 2000)
"Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation."4.80Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000)
" Second, we recommend the use of intravenous caffeine base 10 mg/kg in all infants at risk for postoperative apnea following general anesthesia."4.79Anesthesia and apnea. Perioperative considerations in the former preterm infant. ( Greenspun, JC; Welborn, LG, 1994)
"Apnea of prematurity is one of the most common problems in the neonatal intensive care unit."4.79Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996)
" Caffeine is used for the treatment of apnea of prematurity and as an additive in several analgesics and migraine remedies, and as a panacea for hyperkinetic children."4.77Caffeine: a new look at an age-old drug. ( Gupta, P; Somani, SM, 1988)
"Caffeine and theophylline are effective in the treatment of apnea in the newborn infant."4.76Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979)
"Caffeine is the first-choice drug for the treatment for apnea of prematurity (AOP) in preterm infants and it has been reported that it improves the diaphragm activity."4.31Effects of caffeine on diaphragmatic activity in preterm infants. ( Ciarcià, M; Corsini, I; Dani, C; Fusco, M; Gitto, E; Leonardi, V; Manti, S; Marseglia, L, 2023)
"Therapeutic drug monitoring is generally unnecessary in caffeine treatment for apnea of prematurity, as serum caffeine concentrations in preterm infants are normally markedly lower than those at which caffeine intoxication occurs."4.31Serum caffeine concentrations in preterm infants: a retrospective study. ( Itoh, S; Kawaguchi, N; Konishi, Y; Koyano, K; Kuboi, T; Kusaka, T; Nakamura, S; Nakano, A; Nishioka, K; Noguchi, Y; Okada, H; Sadamura, T; Sugino, M; Tadatomo, Y, 2023)
"In late-preterm infants, caffeine has a clear short-term respiratory stimulant effect, and it increases the arousal frequency to hypoxia."4.12Caffeine is a respiratory stimulant without effect on sleep in the short-term in late-preterm infants. ( Andersson, S; Kirjavainen, T; Seppä-Moilanen, M, 2022)
"Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity."4.12Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022)
"Caffeine has been used as a first-line drug for treatment of apnea neonatorum for decades due to its high safety and effectiveness."4.12Caffeine excites medial parabrachial nucleus neurons of mice by blocking adenosine A1 receptor. ( Cai, X; Chen, J; Gyabaah, AT; Huang, ZL; Li, Y; Li, Z; Ma, C; Shi, H; Tu, Y; Yu, C, 2022)
"The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity."4.12The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022)
"Caffeine is available in an ampoule, used via parenteral and enteral routes in preterm neonates to treat apnea of prematurity (AOP) in neonates of gestational age ≥ 35-40 weeks."4.12Evaluation of pharmaceutically compounded oral caffeine on the impact of medication adherence and risk of readmission among preterm neonates: A single-center quasi-experimental study. ( Ali, A; Ambreen, G; Aslam, MS; Hussain, K; Kumar, M; Salat, MS; Saleem, SM; Shah, SAA; Tahir, A, 2022)
"Caffeine is routinely used in preterm infants for apnea of prematurity."4.12Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range? ( Aghai, ZH; Amendolia, B; Bhat, V; Chung, J; Nakhla, T; Saslow, J; Slater-Myer, L; Tran Lopez, K, 2022)
"Apnea of prematurity can persist despite caffeine therapy in preterm infants."4.02The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021)
"A frequent challenge in Neonatology is the high frequency of spontaneously occurring hypoxemic events, a majority of which are associated with apnea or hypoventilation."4.02Are we over-treating hypoxic spells in preterm infants? ( Conlon, S; Di Fiore, JM; Martin, RJ, 2021)
"Apnea is commonly encountered in children with bronchiolitis."3.96Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit. ( Brossier, D; Denis, M; Faucon, C; Goyer, I; Heuzé, N; Jokic, M; Porcheret, F, 2020)
"Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity."3.96Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020)
"Caffeine to prevent or treat apnea of prematurity in the newborn period is now standard of care for infants born very preterm."3.96Childhood respiratory outcomes after neonatal caffeine therapy. ( Cheong, JLY; Doyle, LW, 2020)
" It appears that infants with apnea of prematurity and those receiving assisted ventilation are the most likely to benefit from caffeine."3.96When to start and stop caffeine and why respiratory status matters. ( Davis, PG, 2020)
"Caffeine is the preferred pharmacologic treatment for apnea of prematurity."3.96Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa. ( Ayede, AI; Ekhaguere, OA; Ezeaka, CV, 2020)
" High doses of caffeine may produce better control of apnea."3.96Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ( Aranda, JV; Beharry, KD, 2020)
"This study explored the feasibility effect and safety of the limb stimulation (LS) for the treatment of neonatal apnea (NAP)."3.88A pilot study of limb stimulation for the treatment of neonatal apnea. ( Dong, LB; Li, YF; Qiao, S; Zhang, Y, 2018)
"To study the clinical effect of early or late administration of caffeine citrate in the prevention and treatment of apnea in very low birth weight (VLBW) infants."3.88[Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants]. ( Chen, X; Cheng, R; Feng, Y; Mao, XN; Qiu, J; Zhao, L, 2018)
"Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and assessed at the Royal Women's Hospital in Melbourne at 11 years of age had expiratory flow rates measured according to the standards of the American Thoracic Society."3.85Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth. ( Cheong, JLY; Doyle, LW; Ranganathan, S, 2017)
"Incidence fell from 74% diagnosed with apnea of prematurity at baseline to 49% diagnosed with CSCPE postimplementation (P<0."3.85Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management. ( Ahlers-Schmidt, CR; Bloom, BT; Engel, M; Powell, MB, 2017)
"Apnea of prematurity affects a small proportion but large absolute number of late preterm infants, with out-patient management variably utilized despite relative clinical equipoise and potential for improved cost-effectiveness."3.85Economics of Home Monitoring for Apnea in Late Preterm Infants. ( Amberson, M; Dukhovny, D; Freiberger, C; Montenegro, BL; Rhein, LM; Veit, L, 2017)
"The pneumotach showed a linear response and clean, steady respiratory traces in which apneas and sighs were clearly visible."3.85A low cost, simplified, and scaleable pneumotachograph and face mask for neonatal mouse respiratory measurements. ( Nanu, R; Ray, RS; Sun, JJ, 2017)
"We recently showed that in 12-day-old male rats exposed to caffeine for 10 consecutive days, progesterone inhibits the respiratory response to hypoxia and increases apnea frequency (Uppari et al."3.85Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats. ( Bairam, A; Joseph, V; Uppari, NP, 2017)
"Caffeine citrate is the treatment of choice for apnea of prematurity (AOP)."3.83The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study. ( Carnielli, VP; Fabbri, L; Ferrari, F; Kiechl-Kohlendorfer, U; Lasagna, G; Lista, G; Papagaroufalis, K; Polackova, R; Saenz, P, 2016)
"Apnea of prematurity (AOP) is nearly universal among very preterm infants, but neither the apnea burden nor its clinical associations have been systematically studied in a large consecutive cohort."3.83Clinical associations of immature breathing in preterm infants: part 1-central apnea. ( Delos, J; Fairchild, K; Kattwinkel, J; Lake, D; Mohr, M; Moorman, JR; Paget-Brown, A; Tabacaru, C, 2016)
"Serum caffeine concentrations >20 μg/ml (100 μmol/l) in infants treated for apnea of prematurity increases TNF-α and decreases IL-10, changes that perhaps are linked to comorbidities."3.83Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine. ( Ahlawat, R; Chavez-Valdez, R; Gauda, EB; Wills-Karp, M, 2016)
"A retrospective observational study was conducted in preterm neonates who received caffeine citrate therapy for apnea of prematurity and had TDM done in the post-extubation period between January 2006 and October 2011."3.83Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. ( Balch, AH; Korgenski, EK; Sherwin, CM; Ward, RM; Yu, T, 2016)
" Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords."3.83[Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016)
" Caffeine is frequently used for apnea of prematurity."3.83Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine? ( Ahmad, A; Klein, B; Mondal, T, 2016)
"Advantages of caffeine for apnea of prematurity have prompted clinicians to use it prophylactically even before apnea."3.81Association of early caffeine administration and neonatal outcomes in very preterm neonates. ( Barrington, K; Lee, SK; Lodha, A; McMillan, DD; Seshia, M; Shah, PS; Yang, J, 2015)
"Apnea is nearly universal among very low birth weight (VLBW) infants, and the associated bradycardia and desaturation may have detrimental consequences."3.81Very long apnea events in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Kattwinkel, J; Lake, DE; Lee, H; Mennen, AC; Mohr, MA; Moorman, JR; Sinkin, RA; Vergales, BD, 2015)
"Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline."3.81Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015)
"Caffeine citrate is widely used to prevent and treat prematurity-associated apnea."3.81The effect of caffeine citrate on neural breathing pattern in preterm infants. ( Beck, J; Lehtonen, L; Leppäsalo, J; Parikka, V; Soukka, H; Zhai, Q, 2015)
"Compare how NICUs within academic centers in Canada, France, and the United States make discharge decisions regarding cardiorespiratory recordings and home use of apnea monitors, oximeters and caffeine."3.81Neonatal intensive care unit discharge of infants with cardiorespiratory events: Tri-country comparison of academic centers. ( Carlos, C; Consenstein, L; Cóté, A; Franco, P; Hageman, J; Kelly, D; McEntire, B; Pellerite, M; Raoux, A; Rusciolelli, C, 2015)
" We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity."3.80Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014)
"Apnea of prematurity, a common disorder, can severely compromise an infant's condition unless correctly diagnosed and treated."3.80Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost. ( Butler, TJ; Firestone, KS; Grow, JL; Kantak, AD, 2014)
" Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis."3.79Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013)
"When asked to address the above question, findings that appeared to be among the most relevant included (1) interventions in the delivery room directed at supporting the physiological transition from intrauterine to extrauterine life rather than actively intervening in it; (2) recent data suggesting that keeping extremely low-gestational age neonates at a pulse oximeter saturation (SpO(2)) of 91-95% would increase their chances of survival compared with aiming for lower SpO(2) values; (3) using caffeine citrate in infants <1250 g with apnoea of prematurity improves neurodevelopmental outcome; (4) injecting antivascular epithelial growth factor into the vitreous seems to be an effective treatment for retinopathy of prematurity and (5) moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy increases the likelihood of survival without neurological impairment."3.79What are the main research findings during the last 5 years that have changed my approach to clinical practice? ( Poets, CF, 2013)
"Three hundred and thirty-eight DBS cards for caffeine measurement were collected from 67 preterm infants (birth weight 0."3.79Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ( Della Pasqua, O; Field, DJ; Gade, S; Kairamkonda, V; Mulla, H; Pandya, HC; Patel, P; Spooner, N, 2013)
"Current knowledge suggests that laryngeal chemoreflexes (LCR) are involved in the occurrence of certain neonatal apneas/bradycardias, especially in the preterm newborn."3.79Effects of caffeine and/or nasal CPAP treatment on laryngeal chemoreflexes in preterm lambs. ( Bairam, A; Boudaa, N; Carrière, V; Germim, PS; Pasquier, JC; Praud, JP; Samson, N, 2013)
"We measured the duration of apnea induced by sustained end-inspiratory lung inflation (the Hering Breuer Reflex, HBR) in unanesthetized infant rat pups aged 4 days (P4) to P20 at body temperatures of 32°C and 36°C."3.79Influence of age, body temperature, GABAA receptor inhibition and caffeine on the Hering-Breuer inflation reflex in unanesthetized rat pups. ( Arnal, AV; Bartlett, D; Gore, JL; Leiter, JC; Rudkin, A, 2013)
"To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age."3.77Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011)
"The mechanisms underlying the therapeutic function of caffeine on apneas in preterm neonates are not well determined."3.76Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. ( Bairam, A; Joseph, V; Julien, CA, 2010)
"Caffeine is a common treatment for apnea of prematurity."3.75Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone. ( Bairam, A; Joseph, V; Kinkead, R; Lajeunesse, Y; Montandon, G, 2009)
"Administration of caffeine citrate (caffeine) has been a central component of the treatment of apnea of prematurity."3.75Acute hemodynamic effects of caffeine administration in premature infants. ( Bin-Nun, A; Ionchev, A; Meadow, W; Soloveychik, V; Sriram, S, 2009)
"Caffeine therapy reduces apnea of prematurity, promotes successful extubation from invasive positive-pressure ventilation, and decreases the incidence of bronchopulmonary dysplasia."3.74Serum caffeine concentrations in preterm neonates. ( Hutchison, AA; Leon, AE; Ma, CX; Michienzi, K, 2007)
"Our goal was to determine the value of measuring plasma caffeine levels in preterm neonates treated with caffeine for apnea."3.74Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? ( Aranda, JV; Botica, ML; Natarajan, G; Thomas, R, 2007)
"Caffeine is an adenosine receptor antagonist commonly used as a respiratory stimulant to treat neonatal apneas of premature newborn."3.73Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats. ( Bairam, A; Kinkead, R; Montandon, G, 2006)
"We correlated plasma and urinary levels of caffeine in preterm infants treated with this drug for apnea of prematurity."3.73Correlation between plasma and urinary caffeine levels in preterm infants. ( Cattarossi, L; Logreco, P; Macagno, F; Savoia, M; Violino, M, 2006)
"Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies."3.73[Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006)
"Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age."3.73[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006)
" This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea."3.71Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001)
"To report the occurrence of apnea and bradycardia in two former pre-term infants who received spinal anaesthesia without inhalational or intravenous anaesthetic agents during inguinal herniorrhaphy."3.70Apnea following spinal anaesthesia in two former pre-term infants. ( Burd, RS; Helikson, MA; Tobias, JD, 1998)
"A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea."3.70Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000)
"To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications."3.70Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000)
"Theophylline has been widely used to treat apnea of premature neonates."3.70Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ( Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999)
"Apnea of prematurity is a common problem in neonatal intensive care nurseries."3.68Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993)
"The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated."3.68Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992)
"The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea."3.68[Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991)
" The infant developed apnea, and not having known the above maternal history, was started on caffeine therapy."3.67Maternal coffee drinking and unusually high concentrations of caffeine in the newborn. ( Khanna, NN; Somani, SM, 1984)
"Caffeine, used for treatment of idiopathic apnea in preterm infants, may have a vasoconstrictive effect on cerebral vessels."3.67Does caffeine affect cerebral blood flow in the preterm infant? ( Baan, J; Ruys, JH; Stijnen, T; Van Bel, F; Van de Bor, M, 1989)
"Administering caffeine citrate is a safe, noninvasive way to treat premature infants with persistent apnea."3.67Caffeine citrate in the NICU. ( Flood, E, 1989)
" Comparison of the groups using quantitative measures of apnea, bradycardia, and periodic breathing obtained from pneumogram analysis and the incidence of monitor alarms on bedside nursing records showed no significant differences."3.67Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication. ( Braun, RJ; Evans, MA; Kelly, DH; McCulloch, KM; Simms, PE, 1989)
"Four premature neonates and eight infants 1-19 months old received caffeine for apnea."3.67Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test. ( Badoual, J; Blais, JC; Carrier, O; d'Athis, P; Moran, C; Olive, G; Plissonnier, M; Pons, G; Rey, E; Richard, MO, 1988)
"Five neonates (4 premature) and 16 infants (6 prematurely born), 15-588 days old, received caffeine as citrate salt for apnea."3.67Developmental changes of caffeine elimination in infancy. ( Badoual, J; Carrier, O; d'Athis, P; Moran, C; Olive, G; Pons, G; Rey, E; Richard, MO, 1988)
"Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"."3.67[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987)
"This review provides an understanding of current problems related to apnea of infancy."3.67Infant apnea. ( Fox, WW; Spitzer, AR, 1986)
"To evaluate the relationship of antecedent maternal smoking and caffeine consumption habits on the occurrence of apnea in their offspring, rates for central and obstructive apnea were analyzed in a cohort of mother-infant pairs."3.67Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study. ( Bendell, D; Duke, JC; Mattice, CD; McCaffree, MA; Orr, WC; Toubas, PL, 1986)
"We report two infants with near miss sudden infant death syndrome events exhibiting seizure disorders after caffeine treatment, suggesting there is an infant subgroup diagnosed as near miss sudden infant death syndrome who have apnoea possibly with seizures whose seizure threshold may be lowered by central nervous system stimulants like caffeine."3.67Apnoea and seizures. ( Aranda, JV; Davis, JM; Metrakos, K, 1986)
" Because caffeine is a respiratory stimulant, its effect on breathing pattern was evaluated in 12 infants with infantile apnea."3.66Effect of caffeine on control of breathing in infantile apnea. ( Aranda, JV; Davis, J; Grondin, D; Trippenbach, T; Turmen, T; Watters, G; Zinman, R, 1983)
"The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea."3.66Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983)
"We studied the effects of intravenous administration of 20 mg/kg caffeine citrate on glucose homeostasis, cardiorespiratory status, and urinary excretion of catecholamines and electrolytes in 12 premature infants with recurrent apnea."3.66The metabolic effects of caffeine in the newborn infant. ( Maisels, MJ; Marks, KH; Rothberg, AD; Ward, RM, 1981)
" Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test."3.66Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982)
"Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea."3.66Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981)
" This view assumes that pharmacologic manipulation of apnea of prematurity is in itself a desirable goal and clearly superior to treatment of apneic episodes when they occur."3.66Adverse effects of caffeine and theophylline in the newborn infant. ( Aranda, JV; Clozel, M; Howell, J, 1981)
"Simultaneous blood and saliva samples were drawn for determination of caffeine and theophylline concentrations in 17 infants receiving caffeine or theophylline therapy for apnea of prematurity."3.66Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. ( Bada, HS; Khanna, NN; Somani, SM, 1980)
"Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants."3.66Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979)
"The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule."3.66Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979)
"Plasma concentrations of theophylline and caffeine in seven premature neonates receiving theophylline orally for treatment of apnea at age one to 9 days were measured by high performance liquid chromatography, ultraviolet spectrophotometry, and mass spectrometry."3.66Metabolism of theophylline to caffeine in premature newborn infants. ( Aranda, JV; Baltassat, P; Bethenod, M; Bory, C; Frederich, A; Porthault, M, 1979)
" Caffeine produced from theophylline may add to the pharmacologic effects of theophylline in newborn infants with apnea."3.66Metabolism of theophylline to caffeine in human fetal liver. ( Aldridge, A; Aranda, JV; Haber, R; Louridas, AT; Thom, P; Vitullo, BB, 1979)
"The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated."3.65Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977)
"If caffeine was found to have a greater effect, this would influence prescribing habits."2.69Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. ( Fang, S; Gamsu, HR; Greenough, A; Marsden, JT; Peters, TJ; Sherwood, RA, 1998)
"Caffeine as first-line treatment demonstrated similar efficacy to theophylline or aminophylline (theophylline ethylenediamine) in 4 small randomised studies."2.41Caffeine citrate: a review of its use in apnoea of prematurity. ( Comer, AM; Figgitt, DP; Perry, CM, 2001)
" Long term use produces tolerance to some of the pharmacological effects."2.39Pharmacological rationale for the clinical use of caffeine. ( Sawynok, J, 1995)
" Population pharmacokinetic modelling of caffeine in Chinese preterm newborn on a population-wide scale was conducted using NONMEM."1.62Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China. ( Gao, XB; Jacqz-Aigrain, E; Jiang, ZH; Ni, SQ; Wang, CH; Wu, YE; Yang, F; Zhao, W; Zheng, Y, 2021)
"Caffeine treatment is a preferred treatment choice."1.62Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants. ( Chen, F; Cheng, R; Guo, HL; He, X; Jia, WW; Li, L; Liu, Y; Lu, KY; Ni, MM; Qiu, JC; Xu, J, 2021)
"Caffeine citrate was used in extremely premature infants at younger gestation, at higher doses, and for longer durations than recommended on the drug label."1.51Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. ( Bendel-Stenzel, E; Chhabra, R; Harper, B; Ku, L; Laughon, M; Moya, F; Payne, EH; Puia-Dumitrescu, M; Smith, PB; Soriano, A; Wade, KC; Zhao, J, 2019)
"To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life."1.46Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ( Datta, AN; Jost, K; Koch, G; Pfister, M; Schulzke, SM; van den Anker, J, 2017)
"The dosing regimen studied was suitable for our local Asian neonates as it resulted in therapeutic caffeine concentrations for adequate treatment of apnoea."1.31Caffeine in apnoeic Asian neonates: a sparse data analysis. ( Chirino-Barcelo, Y; Khoo, YM; Lee, HS; Ong, D; Tan, KL, 2002)
"Caffeine clearance has traditionally been reported as either an absolute value or as directly proportional to body weight."1.30Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ( Anderson, BJ; Gunn, TR; Holford, NH; Johnson, R, 1999)
"Caffeine led to an increase in the mean arterial blood pressure on the first 3 days of therapy, but the heart rate did not change."1.28Cardiovascular effects of caffeine therapy in preterm infants. ( Erickson, R; Sims, ME; Walther, FJ, 1990)
"Caffeine was administered for 3."1.27Effect of caffeine on pneumogram and apnoea of infancy. ( Anwar, M; Graff, M; Hegyi, T; Hiatt, M; Mojica, N; Mondestin, H; Novo, R, 1986)
" Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established."1.27[Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986)
" The elevated blood caffeine levels in breast-fed infants was not related to higher daily dosage of caffeine citrate (4."1.27Delay in caffeine elimination in breast-fed infants. ( Billon, B; Le Guennec, JC, 1987)
"Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively."1.27Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985)
" The mean plasma half-live of theophylline was 22."1.26[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981)
"Caffeine was detectable in plasma at birth, and in preterm infants not receiving theophylline; plasma levels of caffeine tended to be similar to the levels in their mothers' milk."1.26Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ( Brazier, JL; Renaud, H; Ribon, B; Salle, BL, 1979)

Research

Studies (302)

TimeframeStudies, this research(%)All Research%
pre-199073 (24.17)18.7374
1990's28 (9.27)18.2507
2000's41 (13.58)29.6817
2010's104 (34.44)24.3611
2020's56 (18.54)2.80

Authors

AuthorsStudies
Saini, SS1
Kumar, P1
Seppä-Moilanen, M2
Andersson, S2
Kirjavainen, T2
Ariagno, S1
Thorvilson, M1
Andersen, L1
Collura, C1
Yuan, Y1
Yang, Y1
Lei, X1
Dong, W1
Iranpour, R2
Armanian, AM2
Miladi, N1
Feizi, A1
Chavez, L1
Bancalari, E3
Shi, H1
Tu, Y1
Li, Y3
Ma, C1
Gyabaah, AT1
Yu, C1
Li, Z3
Chen, J2
Huang, ZL1
Cai, X1
Smith, A1
Egan, R1
Boyle, MA1
McElligott, F1
Long, JY1
Hu, YH2
Xia, Y1
Du, FF1
Dai, HR2
Tian, M1
Xu, J3
Cheng, R4
Ding, XS2
Guo, HL3
Chen, F3
Xie, JB1
Lin, XZ1
Yun, WZ1
Kassab, YW1
Yao, LM1
Khairuddin, N1
Ming, LC1
Hadi, MA1
Liu, Y3
Lu, KY2
He, X2
Jiao, Z1
Miao, Y2
Zhou, Y1
Zhao, S2
Liu, W2
Wang, A2
Zhang, Y4
Jiang, H2
García-Robles, A1
Solaz-García, Á1
Verdú-Andrés, J1
Andrés, JLP1
Cañada-Martínez, AJ1
Pericás, CC1
Ponce-Rodriguez, HD1
Vento, M1
González, PS1
Dani, C3
Cecchi, A1
Ciarcià, M2
Miselli, F1
Luzzati, M1
Remaschi, G1
Bona, MD1
la Marca, G1
Boni, L1
Ambreen, G1
Kumar, M2
Ali, A1
Shah, SAA1
Saleem, SM1
Tahir, A1
Salat, MS1
Aslam, MS1
Hussain, K1
Prakash, R2
Kannan Loganathan, P1
Nair, V1
Bruschettini, M9
Brattström, P3
Russo, C3
Onland, W4
Davis, PG9
Soll, R4
Fusco, M1
Manti, S1
Marseglia, L1
Leonardi, V1
Corsini, I1
Gitto, E1
Schmidt, B12
Teng, P1
Sugino, M1
Kuboi, T1
Noguchi, Y1
Nishioka, K1
Tadatomo, Y1
Kawaguchi, N1
Sadamura, T1
Nakano, A1
Konishi, Y1
Koyano, K1
Nakamura, S1
Okada, H1
Itoh, S1
Kusaka, T1
Atalah, YEY1
Barış, HE1
Akdere, SK1
Sabancı, M1
Özdemir, H1
Gücüyener, K1
Eralp, EE1
Özek, E1
Boran, P1
Moresco, L1
Sjögren, A1
Marques, KA2
Evans, S1
Avdic, E1
Pessano, S1
Fiander, M2
Roehr, CC1
Maeda, T1
Sekiguchi, K1
Wasada, R1
Ihara, K1
Mitchell, L1
MacFarlane, PM1
Rostas, SE1
McPherson, C1
Johansson, M2
Juhl Jørgensen, K1
Ji, D1
Smith, PB2
Clark, RH1
Zimmerman, KO1
Laughon, M2
Ku, L2
Greenberg, RG1
Heuzé, N1
Goyer, I1
Porcheret, F1
Denis, M1
Faucon, C1
Jokic, M1
Brossier, D1
Nylander Vujovic, S1
Nava, C1
Chung, J1
Tran Lopez, K1
Amendolia, B1
Bhat, V1
Nakhla, T1
Slater-Myer, L1
Saslow, J1
Aghai, ZH1
Alhersh, E1
Abushanab, D1
Al-Shaibi, S1
Al-Badriyeh, D1
Wan, L1
Huang, L2
Chen, P1
He, T1
Liao, ZC1
Ding, Y1
Wang, MJ1
Li, W1
Gan, JM1
Yue, SJ1
Liu, S1
Zhang, X4
Yuan, X1
Yang, L1
Zhang, R1
Wang, X1
Xu, F1
Zhu, C1
Gao, XB1
Zheng, Y1
Yang, F1
Wang, CH1
Jiang, ZH1
Wu, YE1
Jacqz-Aigrain, E1
Ni, SQ1
Zhao, W1
Guo, A1
Zhu, Z1
Xue, J1
Di, X1
Fan, J1
Zhao, P1
Hu, X1
Xie, H1
Oliphant, EA1
McKinlay, CJD1
McNamara, DG2
Alsweiler, JM1
Synnes, A1
Grunau, RE6
Cheong, JLY2
Doyle, LW14
Saroha, V2
Patel, RM3
Qiu, JC1
Li, L1
Jia, WW1
Ni, MM1
Eichenwald, EC1
Ekhaguere, OA1
Ayede, AI1
Ezeaka, CV1
Aranda, JV18
Beharry, KD1
Pournami, F1
Prabhakar, J1
Nandakumar, A1
Nair, PMC1
Jain, N1
Engbers, AGJ1
Völler, S1
Poets, CF7
Knibbe, CAJ1
Reiss, IKM1
Koch, BCP1
Flint, RB1
Simons, SHP1
Conlon, S1
Di Fiore, JM2
Martin, RJ4
Elmowafi, M1
Mohsen, N1
Nour, I2
Nasef, N2
Mohd Kori, AM1
Van Rostenberghe, H1
Ibrahim, NR1
Yaacob, NM1
Nasir, A1
Jiang, Z1
Gao, X1
Liang, J1
Ni, S1
Rosen, C1
Taran, C1
Hanna, M1
Gueta, I1
Loebstein, R1
Strauss, T1
Yarden-Bilavsky, H1
Roberts, RS10
Anderson, PJ5
Asztalos, EV4
Costantini, L3
Dewey, D3
D'Ilario, J3
Moddemann, D5
Nelson, H2
Ohlsson, A5
Solimano, A5
Tin, W6
Shivakumar, M3
Jayashree, P2
Najih, M1
Lewis, LES3
Bhat Y, R1
Kamath, A2
Shashikala, -1
Ranganathan, S1
Abu-Shaweesh, JM1
Koch, G1
Datta, AN1
Jost, K1
Schulzke, SM1
van den Anker, J1
Pfister, M1
O'Halloran, KD2
McDonald, FB2
Khurana, S1
Sujith Kumar Reddy, GV1
Ramesh Bhat, Y1
Chalwadi, UK1
Kalappanavar, NK1
Simon Lewis, LE1
Gentle, SJ1
Travers, CP1
Carlo, WA1
Nagasato, A1
Nakamura, M1
Kamimura, H1
Vliegenthart, R1
Miedema, M2
Hutten, GJ2
van Kaam, AH3
Dix, LML1
van Bel, F2
Baerts, W1
Lemmers, PMA1
Mürner-Lavanchy, IM1
Dobson, NR2
Hunt, CE1
Dempsey, EM1
M, S1
Nayak, K1
Purkayastha, J1
Rantakari, K1
Mikkola, K1
Ley, D2
Huvanandana, J1
Thamrin, C1
Hinder, M1
McEwan, A1
Tracy, MB1
Álvarado Socarras, JL1
Dong, LB1
Li, YF1
Qiao, S1
Feng, Y1
Zhao, L1
Chen, X2
Mao, XN1
Qiu, J1
Vliegenthart, RJS1
Jin, L1
Jain, VG1
Jobe, A1
Kou, C1
Han, D1
Wu, W1
Liu, Z1
Gao, Z1
Puia-Dumitrescu, M1
Zhao, J1
Soriano, A1
Payne, EH1
Harper, B1
Bendel-Stenzel, E1
Moya, F1
Chhabra, R1
Wade, KC1
Zhang, HT1
Lyu, Y1
Wang, LF1
Yang, ZY1
Chawla, R1
Haloi, P1
Singh, M1
Abu Jawdeh, EG1
O'Riordan, M1
Limrungsikul, A1
Bandyopadhyay, A1
Argus, BM1
Nakad, PE1
Supapannachart, S1
Yunis, KA1
Vatlach, S1
Arand, J1
Engel, C1
Schoen, K1
Yu, T2
Stockmann, C1
Spigarelli, MG1
Sherwin, CM2
Ulanovsky, I1
Haleluya, NS1
Blazer, S1
Weissman, A1
O'Brien, K1
Sankaran, K2
Herlenius, E1
Roberts, R1
Kreutzer, K1
Bassler, D1
Maitre, NL2
Chan, J1
Stark, AR2
Lambert, WE1
Aschner, JL1
Key, AP1
Butler, TJ1
Firestone, KS1
Grow, JL1
Kantak, AD1
Marcus, CL2
Meltzer, LJ1
Traylor, J1
Dix, J1
Asztalos, E2
Opie, G1
Biggs, SN1
Nixon, GM2
Narang, I1
Bhattacharjee, R1
Davey, M1
Horne, RS1
Cheshire, M1
Gibbons, J1
Bradford, R1
Khan, SR1
Hassanein, SM1
Gad, GI1
Ismail, RI1
Diab, M1
Lodha, A1
Seshia, M1
McMillan, DD1
Barrington, K1
Yang, J1
Lee, SK1
Shah, PS1
Xu, JL1
Wang, RQ1
Chen, DM1
Araujo, P1
Tufik, S1
Andersen, ML1
Mohr, MA1
Vergales, BD1
Lee, H1
Clark, MT1
Lake, DE1
Mennen, AC1
Kattwinkel, J2
Sinkin, RA1
Moorman, JR2
Fairchild, KD1
Delos, JB1
Ren, J1
Ding, X1
Greer, JJ1
Mohammed, S1
Shabaan, AE1
Shouman, B1
Abdel-Hady, H1
Razak, A1
Nagesh, NK1
Parikka, V1
Beck, J1
Zhai, Q1
Leppäsalo, J1
Lehtonen, L1
Soukka, H1
Bairam, A9
Uppari, N1
Mubayed, S1
Joseph, V5
Doyle, J1
Davidson, D1
Katz, S2
Varela, M1
Demeglio, D1
DeCristofaro, J1
Gauda, E1
MacFarlane, P1
Park, HW1
Lim, G1
Chung, SH1
Chung, S1
Kim, KS1
Kim, SN1
Zhao, Y1
Tian, X1
Liu, G1
Lista, G1
Fabbri, L1
Polackova, R1
Kiechl-Kohlendorfer, U1
Papagaroufalis, K1
Saenz, P1
Ferrari, F1
Lasagna, G1
Carnielli, VP1
Carlos, C1
Hageman, J1
Pellerite, M1
McEntire, B1
Cóté, A1
Raoux, A1
Franco, P1
Rusciolelli, C1
Consenstein, L1
Kelly, D1
Oñatibia-Astibia, A1
Martínez-Pinilla, E1
Franco, R1
Fairchild, K1
Mohr, M1
Paget-Brown, A1
Tabacaru, C1
Lake, D1
Delos, J1
Yu, M1
Huang, JH1
Zhu, R1
Zhang, XZ1
Wu, WY1
Wen, XH1
Faghihian, E1
Salehimehr, N1
Chavez-Valdez, R1
Ahlawat, R1
Wills-Karp, M1
Gauda, EB1
Alansari, K1
Toaimah, FH1
Khalafalla, H1
El Tatawy, LA1
Davidson, BL1
Ahmed, W1
Balch, AH1
Ward, RM2
Korgenski, EK1
Barco, S1
Romantsik, O1
Risso, F1
Gennai, I1
Chinea, B1
Ramenghi, LA1
Tripodi, G1
Cangemi, G1
Chen, C1
Shu, XX1
Yang, XY1
Shi, J1
Tang, J1
Mu, DZ1
Powell, MB1
Ahlers-Schmidt, CR1
Engel, M1
Bloom, BT1
Vliegenthart, RJ1
Ten Hove, CH1
Maheux, A1
Pladys, P1
Laviolle, B1
Atik, A1
Harding, R1
De Matteo, R1
Kondos-Devcic, D1
Cheong, J1
Tolcos, M1
Wei, QZ1
Su, P1
Han, JT1
Duan, YH1
Gray, PH2
Chauhan, M1
Montenegro, BL1
Amberson, M1
Veit, L1
Freiberger, C1
Dukhovny, D2
Rhein, LM1
Ahmad, A1
Mondal, T1
Klein, B1
Sun, JJ1
Nanu, R1
Ray, RS1
Uppari, NP1
Montandon, G2
Lajeunesse, Y1
Kinkead, R2
Soloveychik, V1
Bin-Nun, A1
Ionchev, A1
Sriram, S1
Meadow, W1
Charles, BG2
Townsend, SR1
Steer, PA4
Flenady, VJ2
Shearman, A2
Verder, H1
Bohlin, K1
Kamper, J1
Lindwall, R1
Jonsson, B1
Skouroliakou, M1
Bacopoulou, F1
Markantonis, SL1
Haslam, R1
Sinha, S1
Moriette, G4
Lescure, S1
El Ayoubi, M1
Lopez, E1
Henderson-Smart, DJ8
Julien, CA2
Winckworth, LC1
Powell, E1
Beharry, K2
Valencia, GB1
Natarajan, G2
Davis, J3
Mathew, OP1
Rockley, TJ1
De Paoli, AG2
Lorch, SA1
Kok, JH1
Kamholz, KL1
Wang, N1
Mao, W1
Zupancic, JA1
Davis, P3
Barrington, KJ3
Vavasseur, C1
Cesar, K1
Iolster, T1
White, D1
Latifi, S1
Patel, P1
Mulla, H1
Kairamkonda, V1
Spooner, N1
Gade, S1
Della Pasqua, O1
Field, DJ1
Pandya, HC1
Picone, S1
Bedetta, M1
Paolillo, P1
Boudaa, N1
Samson, N1
Carrière, V1
Germim, PS1
Pasquier, JC1
Praud, JP1
Arnal, AV1
Gore, JL1
Rudkin, A1
Bartlett, D1
Leiter, JC1
Bhatt-Mehta, V1
Schumacher, RE1
Cherif, A2
Marrakchi, Z1
Klouz, A2
Chaouachi, S1
Belkahia, C2
Boukef-Larguèche, S2
Zouari, B1
GESHELIN, SA2
Anderson, BJ2
Marlier, L1
Gaugler, C1
Messer, J1
Sajit, NT1
Steggall, M1
Padmakumar, B1
Hoecker, C1
Nelle, M1
Beedgen, B1
Rengelshausen, J1
Linderkamp, O2
Cattarossi, L2
Violino, M1
Macagno, F2
Logreco, P2
Savoia, M1
Ducrocq, S2
Biran-Mucignat, V2
Lebas, F2
Baudon, JJ2
Gold, F2
Boelle, PY1
Coulter, DM1
Hand, IL1
Noble, LM1
McCallum, AD1
Duke, T1
Leon, AE1
Michienzi, K1
Ma, CX1
Hutchison, AA1
Botica, ML1
Thomas, R1
Stevenson, DK1
Haley, TJ1
Labow, R1
Dandurand, KR1
Scalais, E1
Papageorgiou, A1
Khanna, NN6
Somani, SM7
Turmen, T4
Trippenbach, T2
Grondin, D2
Zinman, R1
Watters, G1
Sourgens, H1
Staib, AH1
Bielicki, M1
von Loewenich, V1
Outerbridge, EW2
Mullner, JW1
Rothberg, AD1
Marks, KH1
Maisels, MJ1
Lönnerholm, G2
Lindström, B2
Paalzow, L1
Sedin, G1
Hargreaves, DB1
Lealman, GT1
Mulley, BA1
Horowitz, DA1
Jablonski, WJ1
Mehta, KA1
Gorodischer, R1
Karplus, M1
Boyer, A1
Miller, J1
Chua, C1
Menke, JA1
Berthou, F1
Alix, D1
Riche, C1
Picart, D1
Dreano, Y1
Gouedard, H1
Banagale, RC1
Bada, HS3
Sasyniuk, BI1
Howell, J1
Clozel, M1
Murat, I2
Blin, MC1
Couchard, M1
Flouvat, B2
De Gamarra, E2
Relier, JP2
Dreyfus-Brisac, C1
Riechert, M2
Lipowsky, G1
Stöckl, H1
Stiegler, H1
Floberg, S1
Sawynok, J1
Lundstrøm, KE1
Larsen, PB2
Brendstrup, L2
Skov, L2
Greisen, G1
Flachs, H1
Welborn, LG3
Greenspun, JC1
Hindmarsh, KW1
Tan, L1
Kalapurackal, M1
Sidhu, J1
Triggs, E1
Charles, B2
Tudehope, D1
Gray, P1
Cowley, D1
Duc, G1
Bucher, HU1
Calhoun, LK1
Lee, TC2
Steer, P5
Flenady, V1
Pesce, AJ1
Rashkin, M1
Kotagal, U1
Fang, S1
Sherwood, RA1
Gamsu, HR1
Marsden, JT1
Peters, TJ1
Greenough, A1
Tobias, JD2
Burd, RS1
Helikson, MA1
Huon, C1
Rey, E4
Mussat, P1
Parat, S1
du Preez, MJ1
Botha, JH1
McFadyen, ML1
Adhikari, M1
Gunn, TR2
Holford, NH1
Johnson, R1
Darraj, S1
Bohnhorst, B1
Subhani, M1
DeCristofaro, JD1
Ahn, HW1
Shin, WG1
Park, KJ1
Suh, OK1
Choi, JH1
Erenberg, A1
Leff, RD1
Haack, DG1
Mosdell, KW1
Hicks, GM1
Wynne, BA1
Bertini, G1
Reali, MF1
Tronchin, M1
Wiechmann, L1
Martelli, E1
Rubaltelli, FF1
Bhatia, J1
Comer, AM1
Perry, CM1
Figgitt, DP1
Bauer, J1
Maier, K1
Hentschel, R1
Aggarwal, R1
Singhal, A1
Deorari, AK1
Paul, VK1
Choi, DM1
Davis, L1
Gannon, BA1
Lee, HS1
Khoo, YM1
Chirino-Barcelo, Y1
Tan, KL1
Ong, D1
Gorman, W2
Bergsteinsson, H1
Gunn, T1
Bory, C2
Baltassat, P2
Porthault, M2
Bethenod, M2
Frederich, A2
Boutroy, MJ3
Vert, P4
Monin, P2
Royer, RJ2
Royer-Morrot, MJ2
Metrakos, K2
Riley, P1
Willis, D1
Cook, CE1
Collinge, JM1
Loughnan, PM1
Aldridge, A2
Neims, AH1
Brazier, JL1
Renaud, H1
Ribon, B1
Salle, BL1
Tin, AA1
Louridas, TA1
Louridas, AT1
Vitullo, BB1
Thom, P1
Haber, R1
Koppe, JG2
de Bruijne, JI1
de Boer, P1
Lucey, JF1
Martinet, Y1
Debry, G1
Romagnoli, C1
De Carolis, MP1
Muzii, U1
Zecca, E1
Tortorolo, G1
Chiarotti, M1
De Giovanni, N1
Carnevale, A1
Scanlon, JE1
Chin, KC1
Morgan, ME1
Durbin, GM1
Hale, KA1
Brown, SS1
van den Anker, JN1
Jongejan, HT1
Sauer, PJ1
Merchant, RH1
Irani, AJ1
Amato, M1
Isenschmid, M1
Hüppi, P1
Soto Alvarez, J1
Sacristán del Castillo, JA1
Aujard, Y1
Morisot, C1
Simoens, C1
Trublin, F1
Lhermitte, M2
Gremillet, C1
Robert, MH1
Lequien, P2
Walther, FJ1
Erickson, R1
Sims, ME1
Van de Bor, M1
Stijnen, T1
Baan, J1
Ruys, JH1
Hannallah, RS2
Fink, R2
Ruttimann, UE2
Hicks, JM1
Fuglsang, G1
Nielsen, K1
Kjaer Nielsen, L1
Sennels, F1
Jakobsen, P1
Thelle, T1
Flood, E1
Noerr, B1
McCulloch, KM1
Braun, RJ1
Simms, PE1
Evans, MA1
Kelly, DH1
Colacino, V1
Janes, A1
Rubini, S1
Zilli, M1
Gupta, P1
Pons, G3
Blais, JC1
Plissonnier, M1
Richard, MO3
Carrier, O3
d'Athis, P2
Moran, C3
Badoual, J3
Olive, G3
Wakamatsu, A1
Umetsu, M1
Motoya, H1
Nakao, T1
Nadkarni, S1
Hay, AW1
Faye, S1
Congdon, PJ1
de Soto, H1
Boeckx, R1
Krauss, AN1
Badonnel, Y1
Houdret, N1
Broly, F1
Roussel, P1
Carpentier, C1
Zaoui, C1
Sacré, L1
Vandenplas, Y1
Spitzer, AR1
Fox, WW1
Toubas, PL1
Duke, JC1
McCaffree, MA1
Mattice, CD1
Bendell, D1
Orr, WC1
Davis, JM1
Anwar, M1
Mondestin, H1
Mojica, N1
Novo, R1
Graff, M1
Hiatt, M1
Hegyi, T1
Reinhardt, D1
Kusenbach, G1
Le Guennec, JC2
Billon, B2
Brouard, C1
Pajot, N1
Walti, H1
Spierer, DN1
Koyama, EA1
Paré, C1
Jamain, B1
Michon, L1
Aubertin, D1
Touratier, P1
Cormier, JP1
Cathely, JP1
Moreau, M1
Rietveld, HJ1
de Wilde, TW1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment With Caffeine of Very Preterm Infant in the Delivery Room: the CAFROOM Feasibility Study[NCT04044976]42 participants (Actual)Interventional2019-08-01Completed
Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784]Phase 118 participants (Anticipated)Interventional2024-06-30Not yet recruiting
Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312]Phase 32,000 participants (Anticipated)Interventional1999-10-31Completed
The Effect of Standardizing the Definition and Approach to a Clinically Significant Cardiopulmonary Event in Infants Less Than 30 Weeks on Length of Stay[NCT03414671]160 participants (Actual)Observational2018-06-01Completed
Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357]Phase 3201 participants (Actual)Interventional2009-11-30Completed
Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support.[NCT04001712]Phase 354 participants (Actual)Interventional2019-04-05Completed
A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473]Phase 424 participants (Actual)Interventional2017-02-01Active, not recruiting
High Versus Low Dose Caffeine as Respiratory Stimulant in Preterm Infants[NCT04144712]Phase 180 participants (Anticipated)Interventional2019-04-01Recruiting
Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953]110 participants (Anticipated)Interventional2022-07-21Recruiting
Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)[NCT01435486]90 participants (Actual)Interventional2011-11-30Completed
A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182]Phase 2/Phase 37 participants (Actual)Interventional2011-10-31Terminated (stopped due to Low recruitment rate)
Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial[NCT06026163]Phase 2/Phase 3134 participants (Anticipated)Interventional2023-10-31Not yet recruiting
WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability[NCT04528030]17 participants (Anticipated)Interventional2021-04-01Not yet recruiting
[NCT01066728]Phase 2/Phase 387 participants (Actual)Interventional2001-08-31Completed
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia[NCT04447989]Phase 2120 participants (Anticipated)Interventional2021-05-27Recruiting
Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants[NCT02293824]50 participants (Anticipated)Observational2014-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

62 reviews available for caffeine and Apnea

ArticleYear
Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved.
    Pediatric pulmonology, 2022, Volume: 57, Issue:6

    Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; In

2022
Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant.
    Neonatology, 2022, Volume: 119, Issue:4

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa

2022
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2022, Jul-15, Volume: 24, Issue:7

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa

2022
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
    PloS one, 2022, Volume: 17, Issue:9

    Topics: Aminophylline; Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases

2022
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity.
    The Cochrane database of systematic reviews, 2023, 04-11, Volume: 4

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Humans; Infant; Infant, Extremely Premature; Inf

2023
Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2023, Volume: 36, Issue:1

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Respirat

2023
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants.
    The Cochrane database of systematic reviews, 2023, 10-04, Volume: 10

    Topics: Aminophylline; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Hearing Loss; Humans; Infa

2023
Doxapram for the prevention and treatment of apnea in preterm infants.
    The Cochrane database of systematic reviews, 2023, 10-25, Volume: 10

    Topics: Aminophylline; Apnea; Caffeine; Doxapram; Humans; Infant, Newborn; Infant, Premature; Lung Diseases

2023
Methylxanthine for the prevention and treatment of apnea in preterm infants.
    The Cochrane database of systematic reviews, 2023, 10-31, Volume: 10

    Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur

2023
Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea.
    Respiratory physiology & neurobiology, 2020, Volume: 273

    Topics: Animals; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Newb

2020
Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine.
    Neonatal network : NN, 2019, Nov-01, Volume: 38, Issue:6

    Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System; Central Nervous System Stimulants; Dose-

2019
Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review.
    Pediatric research, 2020, Volume: 88, Issue:3

    Topics: Apnea; Caffeine; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Premature; I

2020
Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.
    Paediatric drugs, 2020, Volume: 22, Issue:4

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive

2020
Neurodevelopmental outcomes after neonatal caffeine therapy.
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; D

2020
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationsh

2020
National and international guidelines for neonatal caffeine use: Are they evidenced-based?
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Evidence-Based Medicine; Humans; Infan

2020
Caffeine use in the neonatal intensive care unit.
    Seminars in fetal & neonatal medicine, 2017, Volume: 22, Issue:5

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Intensive Care Units, Neonatal

2017
Caffeine controversies.
    Current opinion in pediatrics, 2018, Volume: 30, Issue:2

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Drug Administration

2018
High versus standard dose caffeine for apnoea: a systematic review.
    Archives of disease in childhood. Fetal and neonatal edition, 2018, Volume: 103, Issue:6

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Dose-Response Relati

2018
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
    Pediatric research, 2018, Volume: 84, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot

2018
High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant Mortality; Infant, Newbor

2019
Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis.
    BioMed research international, 2018, Volume: 2018

    Topics: Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prema

2018
Is early caffeine therapy safe and effective for ventilated preterm infants?
    Journal of perinatology : official journal of the California Perinatal Association, 2019, Volume: 39, Issue:5

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa

2019
Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.
    Paediatric drugs, 2014, Volume: 16, Issue:2

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Drug Monitoring; Humans; Infant, Prema

2014
Caffeine for apnea of prematurity: a neonatal success story.
    Neonatology, 2014, Volume: 105, Issue:4

    Topics: Animals; Apnea; Birth Weight; Caffeine; Cost-Benefit Analysis; Drug Costs; Gestational Age; Humans;

2014
An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats.
    Advances in experimental medicine and biology, 2015, Volume: 860

    Topics: Age Factors; Animals; Animals, Newborn; Apnea; Caffeine; Heart Rate; Hypoxia; Progesterone; Rats; Re

2015
Cardiorespiratory events in preterm infants: interventions and consequences.
    Journal of perinatology : official journal of the California Perinatal Association, 2016, Volume: 36, Issue:4

    Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway

2016
Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis.
    Journal of Korean medical science, 2015, Volume: 30, Issue:12

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Enterocolitis, Necrotizing; Humans; Infant; I

2015
The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.
    Respiratory medicine, 2016, Volume: 112

    Topics: Adolescent; Apnea; Asthma; Bronchodilator Agents; Caffeine; Child; Child, Preschool; Cough; Humans;

2016
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
    Neonatology, 2017, Volume: 111, Issue:2

    Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa

2017
The Role of Caffeine in Noninvasive Respiratory Support.
    Clinics in perinatology, 2016, Volume: 43, Issue:4

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb

2016
Caffeine for apnea of prematurity: Effects on the developing brain.
    Neurotoxicology, 2017, Volume: 58

    Topics: Animals; Apnea; Brain; Caffeine; Central Nervous System Stimulants; Humans

2017
Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia.
    Acta paediatrica (Oslo, Norway : 1992), 2009, Volume: 98, Issue:9

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Combined M

2009
[Apnea of prematurity: what's new?].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2010, Volume: 17, Issue:2

    Topics: Apnea; Bradycardia; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Caffeine; Central Nervous Sys

2010
Interventions for apnoea of prematurity: a personal view.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:2

    Topics: Amino Acids; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant,

2010
Caffeine versus theophylline for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn;

2010
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
    Archives of disease in childhood, 2010, Volume: 95, Issue:9

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities;

2010
Caffeine impact on neonatal morbidities.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2010, Volume: 23 Suppl 3

    Topics: Animals; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premat

2010
Apnea of prematurity: pathogenesis and management strategies.
    Journal of perinatology : official journal of the California Perinatal Association, 2011, Volume: 31, Issue:5

    Topics: Apnea; Arrhythmias, Cardiac; Brain Stem; Caffeine; Central Nervous System Stimulants; Continuous Pos

2011
Methylxanthine treatment for apnoea in preterm infants.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa

2010
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I

2010
Caffeine citrate: when and for how long. A literature review.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2012, Volume: 25 Suppl 3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Infant, Newborn; Infant, Prema

2012
Treatment of apnea of prematurity.
    Paediatric drugs, 2003, Volume: 5, Issue:3

    Topics: Aminophylline; Apnea; Caffeine; Clinical Trials as Topic; Doxapram; Humans; Infant, Newborn; Infant,

2003
Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia.
    Paediatric anaesthesia, 2004, Volume: 14, Issue:7

    Topics: Anesthesia, General; Apnea; Bronchiolitis; Caffeine; Clinical Trials as Topic; Humans; Infant; Infan

2004
Evidence behind the WHO guidelines: hospital care for children: is caffeine useful in the prevention of apnoea of prematurity?
    Journal of tropical pediatrics, 2007, Volume: 53, Issue:2

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Hospitals; Humans; Infant, Newborn; Infant, Prem

2007
Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults.
    Drug metabolism reviews, 1983, Volume: 14, Issue:2

    Topics: Adult; Age Factors; Apnea; Asthma; Biotransformation; Bradycardia; Caffeine; Child; Female; Half-Lif

1983
Pharmacological rationale for the clinical use of caffeine.
    Drugs, 1995, Volume: 49, Issue:1

    Topics: Animals; Apnea; Caffeine; Central Nervous System; Headache; Humans; Hypotension; Obesity; Pain; Phos

1995
Anesthesia and apnea. Perioperative considerations in the former preterm infant.
    Pediatric clinics of North America, 1994, Volume: 41, Issue:1

    Topics: Age Factors; Anemia; Anesthesia; Apnea; Bradycardia; Caffeine; Clinical Protocols; Gestational Age;

1994
Pharmacologic management of apnea of prematurity.
    The Journal of perinatal & neonatal nursing, 1996, Volume: 9, Issue:4

    Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature,

1996
Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry.
    Clinical chemistry, 1998, Volume: 44, Issue:5

    Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Lung Diseases, Obs

1998
Caffeine versus theophylline for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn;

2000
Postoperative caffeine for preventing apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In

2000
Methylxanthine treatment for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2000, Issue:2

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa

2000
Current options in the management of apnea of prematurity.
    Clinical pediatrics, 2000, Volume: 39, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema

2000
Caffeine citrate: a review of its use in apnoea of prematurity.
    Paediatric drugs, 2001, Volume: 3, Issue:1

    Topics: Apnea; Brain; Caffeine; Central Nervous System Stimulants; Citrates; Drug Combinations; Heart Rate;

2001
Methylxanthine treatment for apnea in preterm infants.
    The Cochrane database of systematic reviews, 2001, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa

2001
Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants.
    The Cochrane database of systematic reviews, 2001, Issue:4

    Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In

2001
Apnea in the newborn.
    Indian journal of pediatrics, 2001, Volume: 68, Issue:10

    Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; In

2001
Theophylline or caffeine: which is best for apnea of prematurity?
    Neonatal network : NN, 2000, Volume: 19, Issue:8

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; In

2000
Methylxanthines in apnea of prematurity.
    Clinics in perinatology, 1979, Volume: 6, Issue:1

    Topics: Apnea; Caffeine; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Respi

1979
Pharmacotherapy of neonatal apnea.
    Indian pediatrics, 1991, Volume: 28, Issue:11

    Topics: Apnea; Caffeine; Citrates; Doxapram; Drug Combinations; Humans; Infant, Newborn; Theophylline

1991
Caffeine: a new look at an age-old drug.
    International journal of clinical pharmacology, therapy, and toxicology, 1988, Volume: 26, Issue:11

    Topics: Apnea; Arteriosclerosis; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Neoplasms

1988

Trials

53 trials available for caffeine and Apnea

ArticleYear
Effect of Prophylactic Caffeine on Noninvasive Respiratory Support in Preterm Neonates Weighing 1250-2000 g: A Randomized Controlled Trial.
    Archives of Iranian medicine, 2022, 02-01, Volume: 25, Issue:2

    Topics: Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant; Infant, Newborn; Infant, Prema

2022
Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial.
    Paediatric drugs, 2023, Volume: 25, Issue:1

    Topics: Apnea; Caffeine; Delivery Rooms; Gestational Age; Humans; Infant, Newborn; Infant, Premature

2023
Caffeine citrate maintenance doses effect on extubation and apnea postventilation in preterm infants.
    Pediatric pulmonology, 2020, Volume: 55, Issue:10

    Topics: Airway Extubation; Apnea; Caffeine; Citrates; Continuous Positive Airway Pressure; Double-Blind Meth

2020
[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2020, Volume: 22, Issue:7

    Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Humans; Infant; Infant, Newborn; Infant, Premature;

2020
Early application of caffeine improves white matter development in very preterm infants.
    Respiratory physiology & neurobiology, 2020, Volume: 281

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Diffusion Tensor Imaging; Fem

2020
(Rad 8)Caffeine prophylaxis to improve intermittent hypoxaemia in infants born late preterm: a randomised controlled dosage trial (Latte Dosage Trial).
    BMJ open, 2020, 10-20, Volume: 10, Issue:10

    Topics: Apnea; Caffeine; Female; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; New Zealand; P

2020
Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial.
    Indian journal of pediatrics, 2021, Volume: 88, Issue:12

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu

2021
Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2022, Volume: 35, Issue:25

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Ox

2022
A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity.
    International journal of environmental research and public health, 2021, 04-23, Volume: 18, Issue:9

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases

2021
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
    JAMA pediatrics, 2017, 06-01, Volume: 171, Issue:6

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De

2017
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
    JAMA pediatrics, 2017, 06-01, Volume: 171, Issue:6

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De

2017
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
    JAMA pediatrics, 2017, 06-01, Volume: 171, Issue:6

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De

2017
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
    JAMA pediatrics, 2017, 06-01, Volume: 171, Issue:6

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De

2017
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
    Indian pediatrics, 2017, Apr-15, Volume: 54, Issue:4

    Topics: Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male

2017
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
    Journal of neonatal-perinatal medicine, 2017, Volume: 10, Issue:4

    Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities;

2017
Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
    Pediatrics, 2018, Volume: 141, Issue:5

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child; Child Development; Double-Blind Method; F

2018
Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups.
    Journal of tropical pediatrics, 2019, 06-01, Volume: 65, Issue:3

    Topics: Aminophylline; Apnea; Caffeine; Dose-Response Relationship, Drug; Echocardiography; Female; Gestatio

2019
Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea.
    Minerva pediatrica, 2020, Volume: 72, Issue:2

    Topics: Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrat

2020
[Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2019, Volume: 21, Issue:6

    Topics: Apnea; Caffeine; Child; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Very L

2019
The effects of caffeine on heart rate variability in newborns with apnea of prematurity.
    Journal of perinatology : official journal of the California Perinatal Association, 2014, Volume: 34, Issue:8

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Heart Rate; Humans; Infant, Newborn; Inf

2014
Reduction in developmental coordination disorder with neonatal caffeine therapy.
    The Journal of pediatrics, 2014, Volume: 165, Issue:2

    Topics: Apnea; Caffeine; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Infan

2014
Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.
    American journal of respiratory and critical care medicine, 2014, Oct-01, Volume: 190, Issue:7

    Topics: Actigraphy; Apnea; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Double-Blin

2014
High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial.
    European journal of pediatrics, 2015, Volume: 174, Issue:7

    Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relat

2015
Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge.
    Journal of perinatology : official journal of the California Perinatal Association, 2016, Volume: 36, Issue:2

    Topics: Apnea; Caffeine; Drug Monitoring; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Infan

2016
[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2016, Volume: 54, Issue:1

    Topics: Apnea; Birth Weight; Caffeine; Citrates; Female; Gestational Age; Humans; Infant, Newborn; Infant, P

2016
[Effect of caffeine citrate on early pulmonary function in preterm infants with apnea].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016, Volume: 18, Issue:3

    Topics: Aminophylline; Apnea; Caffeine; Citrates; Continuous Positive Airway Pressure; Female; Humans; Infan

2016
Caffeine Administration to Prevent Apnea in Very Premature Infants.
    Pediatrics and neonatology, 2016, Volume: 57, Issue:5

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Female; Gestational Age; Hu

2016
Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial.
    The Journal of pediatrics, 2016, Volume: 177

    Topics: Apnea; Bronchiolitis; Caffeine; Citrates; Double-Blind Method; Female; Humans; Infant; Male

2016
[Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016, Volume: 18, Issue:12

    Topics: Apnea; Caffeine; Female; Humans; Infant; Infant, Newborn; Male; Prospective Studies; Respiratory Dis

2016
Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:6

    Topics: Apnea; Biological Availability; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response

2008
Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
    Journal of paediatrics and child health, 2009, Volume: 45, Issue:10

    Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Drug Therapy, Combination

2009
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
    The Journal of pediatrics, 2010, Volume: 156, Issue:3

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati

2010
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch

2012
[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2003, Volume: 10, Issue:6

    Topics: Administration, Oral; Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, High Press

2003
[Monohydrated caffeine: which dosage is effective in the treatment of apnea of prematurity?].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2003, Volume: 10, Issue:8

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Humans; Infant

2003
Olfactory stimulation prevents apnea in premature newborns.
    Pediatrics, 2005, Volume: 115, Issue:1

    Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The

2005
Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants.
    Archives of disease in childhood. Fetal and neonatal edition, 2006, Volume: 91, Issue:1

    Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Caffeine; Carotid Artery, Internal; Celiac Art

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th

2006
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Long-term effects of caffeine therapy for apnea of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development

2007
Effects of caffeine being studied for treatment of apnea in newborns.
    Canadian Medical Association journal, 1983, Aug-01, Volume: 129, Issue:3

    Topics: Apnea; Caffeine; Clinical Trials as Topic; Double-Blind Method; Humans; Infant, Newborn; Infant, New

1983
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
    The Journal of pediatrics, 1981, Volume: 99, Issue:6

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Prospective Studies; Recurren

1981
Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline.
    Acta paediatrica (Oslo, Norway : 1992), 1995, Volume: 84, Issue:1

    Topics: Aminophylline; Analysis of Variance; Apnea; Caffeine; Cerebrovascular Circulation; Humans; Infant, N

1995
Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates.
    Acta paediatrica (Oslo, Norway : 1992), 1995, Volume: 84, Issue:4

    Topics: Apnea; Bradycardia; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Prematur

1995
Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity.
    Therapeutic drug monitoring, 1996, Volume: 18, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Double-Bli

1996
Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity.
    Clinical pharmacology and therapeutics, 1997, Volume: 61, Issue:6

    Topics: Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Gestational Age; Humans; Infant, Newb

1997
Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
    European journal of pediatrics, 1998, Volume: 157, Issue:5

    Topics: Anemia; Apnea; Caffeine; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu

1998
Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study.
    Acta paediatrica (Oslo, Norway : 1992), 1998, Volume: 87, Issue:11

    Topics: Apnea; Blood Pressure; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Doxapram; H

1998
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
    Biology of the neonate, 1999, Volume: 76, Issue:4

    Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo

1999
Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study.
    Pharmacotherapy, 2000, Volume: 20, Issue:6

    Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Drug Combinations; Female; Humans; Infant; Infant, N

2000
Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment.
    Biology of the neonate, 2000, Volume: 78, Issue:1

    Topics: Aminophylline; Apnea; Birth Weight; Blood Flow Velocity; Blood Volume; Caffeine; Central Nervous Sys

2000
Caffeine or theophylline for neonatal apnoea?
    Archives of disease in childhood, 1992, Volume: 67, Issue:4 Spec No

    Topics: Apnea; Caffeine; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Infant, Premature; Theop

1992
High-dose caffeine suppresses postoperative apnea in former preterm infants.
    Anesthesiology, 1989, Volume: 71, Issue:3

    Topics: Anesthesia, General; Apnea; Bradycardia; Caffeine; Clinical Trials as Topic; Double-Blind Method; He

1989
The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants.
    Acta paediatrica Scandinavica, 1989, Volume: 78, Issue:5

    Topics: Administration, Oral; Apnea; Bradycardia; Caffeine; Clinical Trials as Topic; Double-Blind Method; F

1989
The use of caffeine in the control of post-anesthetic apnea in former premature infants.
    Anesthesiology, 1988, Volume: 68, Issue:5

    Topics: Anesthesia, Inhalation; Apnea; Caffeine; Clinical Trials as Topic; Double-Blind Method; Hernia, Ingu

1988
Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant.
    The Journal of pediatrics, 1987, Volume: 110, Issue:4

    Topics: Apnea; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas

1987
Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants.
    American journal of diseases of children (1960), 1985, Volume: 139, Issue:7

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline

1985

Other Studies

187 other studies available for caffeine and Apnea

ArticleYear
Caffeine Duration for Apnea of Prematurity: All Bets Are Off!
    Indian journal of pediatrics, 2021, Volume: 88, Issue:12

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases

2021
Caffeine is a respiratory stimulant without effect on sleep in the short-term in late-preterm infants.
    Pediatric research, 2022, Volume: 92, Issue:3

    Topics: Apnea; Caffeine; Carbon Dioxide; Central Nervous System Stimulants; Humans; Hypoxia; Infant; Infant,

2022
Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
    Journal of palliative medicine, 2022, Volume: 25, Issue:5

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant; Infant, Newborn; Infant,

2022
Caffeine excites medial parabrachial nucleus neurons of mice by blocking adenosine A1 receptor.
    Brain research, 2022, 09-01, Volume: 1790

    Topics: Adenosine; Animals; Apnea; Caffeine; Mice; Neurons; Parabrachial Nucleus; Receptor, Adenosine A1; Re

2022
The Use of Caffeine for Apnoea Associated with Trisomy 13 and Trisomy 18.
    Irish medical journal, 2021, 09-20, Volume: 114, Issue:8

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Trisomy 13 Syndrome; Trisomy 18 Syndrom

2021
Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix.
    Biomedical chromatography : BMC, 2022, Volume: 36, Issue:11

    Topics: Animals; Apnea; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature; Rats; Tandem

2022
Effectiveness and safety of early versus late caffeine therapy in managing apnoea of prematurity among preterm infants: a retrospective cohort study.
    International journal of clinical pharmacy, 2022, Volume: 44, Issue:5

    Topics: Apnea; Caffeine; Cohort Studies; Humans; Infant; Infant, Newborn; Infant, Premature; Retrospective S

2022
Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms.
    Pharmacological research, 2022, Volume: 184

    Topics: Apnea; Caffeine; Erythromycin; Humans; Infant; Infant, Newborn; Infant, Premature; Polymorphism, Gen

2022
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
    European journal of pediatrics, 2022, Volume: 181, Issue:12

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa

2022
Evaluation of pharmaceutically compounded oral caffeine on the impact of medication adherence and risk of readmission among preterm neonates: A single-center quasi-experimental study.
    PloS one, 2022, Volume: 17, Issue:11

    Topics: Apnea; Caffeine; Gestational Age; Humans; Infant; Infant, Newborn; Medication Adherence; Patient Rea

2022
It is time for a rethink about caffeine therapy for apnoea of prematurity.
    Acta paediatrica (Oslo, Norway : 1992), 2023, Volume: 112, Issue:9

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas

2023
Comments on our paper about using caffeine for preterm infants helped to fill knowledge gaps.
    Acta paediatrica (Oslo, Norway : 1992), 2023, Volume: 112, Issue:9

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature

2023
Effects of caffeine on diaphragmatic activity in preterm infants.
    Pediatric pulmonology, 2023, Volume: 58, Issue:7

    Topics: Apnea; Caffeine; Diaphragm; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Sle

2023
Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing.
    The Journal of pediatrics, 2023, Volume: 259

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas

2023
Serum caffeine concentrations in preterm infants: a retrospective study.
    Scientific reports, 2023, 06-26, Volume: 13, Issue:1

    Topics: Apnea; Caffeine; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Retrospective

2023
Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2023, Dec-01, Volume: 19, Issue:12

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Polysomnography; Sleep

2023
Caffeine not associated with irritable behaviour in very low-birth-weight infants.
    Early human development, 2019, Volume: 137

    Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Female; Hu

2019
Is earlier better when it comes giving caffeine to preterm infants or are we risking unnecessary treatment and serious harm?
    Acta paediatrica (Oslo, Norway : 1992), 2020, Volume: 109, Issue:3

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases

2020
Wide variation in caffeine discontinuation timing in premature infants.
    Journal of perinatology : official journal of the California Perinatal Association, 2020, Volume: 40, Issue:2

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Cohort Studies; Combined Modality Ther

2020
Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2020, Volume: 27, Issue:1

    Topics: Apnea; Bronchiolitis; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Citrates; F

2020
Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2022, Volume: 35, Issue:3

    Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Re

2022
Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:3

    Topics: Apnea; Caffeine; Child; China; Humans; Infant; Infant, Newborn; Infant, Premature; Marketing

2021
Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea.
    Journal of clinical pharmacy and therapeutics, 2020, Volume: 45, Issue:6

    Topics: Apnea; Asian People; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant,

2020
Childhood respiratory outcomes after neonatal caffeine therapy.
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Child; Citrates; Duc

2020
When to start and stop caffeine and why respiratory status matters.
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Hypoxia; Infant; Infant, Newbo

2020
Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants.
    Advances in therapy, 2021, Volume: 38, Issue:1

    Topics: Apnea; Caffeine; China; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Reference Stan

2021
Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa.
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Africa South of the Sahara; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Costs and

2020
Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns.
    Seminars in fetal & neonatal medicine, 2020, Volume: 25, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Huma

2020
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
    Neonatology, 2021, Volume: 118, Issue:1

    Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di

2021
Are we over-treating hypoxic spells in preterm infants?
    Seminars in fetal & neonatal medicine, 2021, Volume: 26, Issue:3

    Topics: Apnea; Caffeine; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dis

2021
Simultaneous quantitation of serum caffeine and its metabolites by ultra-high-performance liquid chromatography-tandem mass spectrometry for CYP1A2 activity prediction in premature infants.
    Biomedical chromatography : BMC, 2021, Volume: 35, Issue:9

    Topics: Apnea; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Female; Humans; Infa

2021
Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study.
    Journal of perinatology : official journal of the California Perinatal Association, 2021, Volume: 41, Issue:9

    Topics: Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Prospective Studies

2021
Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
    American journal of respiratory and critical care medicine, 2017, 11-15, Volume: 196, Issue:10

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Female; Follow-Up Studies; Humans; Infant, Newbo

2017
Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
    The Journal of pediatrics, 2017, Volume: 191

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationsh

2017
Pharmacotherapies for apnoea of prematurity: time to pause and consider targeted sex-specific strategies?
    Experimental physiology, 2018, 02-01, Volume: 103, Issue:2

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male

2018
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns.
    Indian pediatrics, 2017, 12-15, Volume: 54, Issue:12

    Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2017
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns: Author's Reply.
    Indian pediatrics, 2017, 12-15, Volume: 54, Issue:12

    Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2017
[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2018, Volume: 138, Issue:2

    Topics: Administration, Oral; Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Prema

2018
Effects of caffeine on the preterm brain: An observational study.
    Early human development, 2018, Volume: 120

    Topics: Apnea; Brain; Caffeine; Electroencephalography; Gestational Age; Humans; Infant, Newborn; Infant, Pr

2018
Caffeine therapy for apnoea of prematurity: Wake up to the fact that sex matters.
    Experimental physiology, 2018, Volume: 103, Issue:10

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Sex Ch

2018
Caffeine and supplemental oxygen effectively suppress periodic breathing with only minor effects during long episodes of apnoea in preterm infants.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Newborn; Infant, Prematu

2019
The effect of caffeine loading on cerebral autoregulation in preterm infants.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cerebrovascular Circulation; Cohort Studies; Fem

2019
Caffeine use in preterm infants: from magic to uncertainty.
    Archivos argentinos de pediatria, 2018, 12-01, Volume: 116, Issue:6

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Pre

2018
High versus low dose caffeine in preterm infants.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu

2019
A pilot study of limb stimulation for the treatment of neonatal apnea.
    Medicine, 2018, Volume: 97, Issue:49

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Foot; Hand; Humans; Infant, Newborn; Inf

2018
[Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2018, Volume: 20, Issue:12

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Citrates; Humans; Infant; Infant, Very Low Birth

2018
High versus low dose caffeine in preterm infants.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu

2019
Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth: Results From the Caffeine for Apnea of Prematurity Trial.
    JAMA pediatrics, 2019, 05-01, Volume: 173, Issue:5

    Topics: Apnea; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Child; Female; Follow-Up S

2019
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
    The Journal of pediatrics, 2019, Volume: 211

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Ductus Arteriosus, Paten

2019
The use of caffeine for the treatment of apnea of prematurity and bradycardia in a holoprosencephalic child with cleft lip and palate.
    Journal of clinical anesthesia, 2013, Volume: 25, Issue:8

    Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Citrates; Cleft Lip; Cleft Palate;

2013
Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
    Journal of neonatal-perinatal medicine, 2013, Volume: 6, Issue:3

    Topics: Apnea; Australia; Caffeine; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice;

2013
Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity.
    Neonatology, 2014, Volume: 105, Issue:2

    Topics: Apnea; Caffeine; Chemistry, Pharmaceutical; Citrates; Drug-Related Side Effects and Adverse Reaction

2014
Effects of caffeine treatment for apnea of prematurity on cortical speech-sound differentiation in preterm infants.
    Journal of child neurology, 2015, Volume: 30, Issue:3

    Topics: Acoustic Stimulation; Analysis of Variance; Apnea; Brain Mapping; Caffeine; Central Nervous System S

2015
Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost.
    Joint Commission journal on quality and patient safety, 2014, Volume: 40, Issue:6

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Documentation; Gestational Age; Hospital Costs;

2014
Current management of apnea in premature infants: is caffeine the magic bullet?
    Early human development, 2014, Volume: 90 Suppl 2

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Respiration, Artificial; Respiratory Sy

2014
Former preterm infants, caffeine was good for you, but now beware of snoring!
    American journal of respiratory and critical care medicine, 2014, Oct-01, Volume: 190, Issue:7

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal

2014
Effect of caffeine on preterm infants' cerebral cortical activity: an observational study.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2015, Volume: 28, Issue:17

    Topics: Apnea; Blood Pressure; Caffeine; Cerebral Cortex; Electroencephalography; Female; Gestational Age; H

2015
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
    JAMA pediatrics, 2015, Volume: 169, Issue:1

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum

2015
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
    JAMA pediatrics, 2015, Volume: 169, Issue:1

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum

2015
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
    JAMA pediatrics, 2015, Volume: 169, Issue:1

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum

2015
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
    JAMA pediatrics, 2015, Volume: 169, Issue:1

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum

2015
[Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2014, Volume: 16, Issue:11

    Topics: Aminophylline; Apnea; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature; Male;

2014
Neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
    American journal of respiratory and critical care medicine, 2014, Dec-01, Volume: 190, Issue:11

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal

2014
Reply: neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
    American journal of respiratory and critical care medicine, 2014, Dec-01, Volume: 190, Issue:11

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal

2014
Very long apnea events in preterm infants.
    Journal of applied physiology (Bethesda, Md. : 1985), 2015, Mar-01, Volume: 118, Issue:5

    Topics: Apnea; Bradycardia; Caffeine; Continuous Positive Airway Pressure; Female; Heart Rate; Humans; Infan

2015
Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats.
    American journal of respiratory and critical care medicine, 2015, Mar-15, Volume: 191, Issue:6

    Topics: Analgesics, Opioid; Animals; Animals, Newborn; Apnea; Brain Stem; Caffeine; Disease Models, Animal;

2015
Caffeine in a term neonate with apnea.
    Indian pediatrics, 2015, Volume: 52, Issue:4

    Topics: Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Male; Ventilator Wean

2015
The effect of caffeine citrate on neural breathing pattern in preterm infants.
    Early human development, 2015, Volume: 91, Issue:10

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant, Newborn; Infan

2015
The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study.
    Neonatology, 2016, Volume: 109, Issue:3

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Europe; Female; Humans; Infant, Newborn; Infa

2016
Neonatal intensive care unit discharge of infants with cardiorespiratory events: Tri-country comparison of academic centers.
    Journal of neonatal-perinatal medicine, 2015, Volume: 8, Issue:4

    Topics: Academic Medical Centers; Apnea; Caffeine; Canada; Central Nervous System Stimulants; Clinical Decis

2015
Clinical associations of immature breathing in preterm infants: part 1-central apnea.
    Pediatric research, 2016, Volume: 80, Issue:1

    Topics: Algorithms; Apnea; Caffeine; Cohort Studies; Electrocardiography; Enterocolitis, Necrotizing; Female

2016
Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine.
    Pediatric research, 2016, Volume: 80, Issue:1

    Topics: Apgar Score; Apnea; Caffeine; Central Nervous System Stimulants; Comorbidity; Cyclic AMP; Cytokines;

2016
Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates.
    BMC pharmacology & toxicology, 2016, 06-07, Volume: 17, Issue:1

    Topics: Apnea; Caffeine; Citrates; Drug Monitoring; Female; Heart Rate; Humans; Infant, Newborn; Infant, Pre

2016
DBS-LC-MS/MS assay for caffeine: validation and neonatal application.
    Bioanalysis, 2016, Volume: 8, Issue:18

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, Liquid; Dried Blood Spot Testing

2016
[Current research status of drug therapy for apnea of prematurity].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016, Volume: 18, Issue:9

    Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2016
Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management.
    Journal of perinatology : official journal of the California Perinatal Association, 2017, Volume: 37, Issue:1

    Topics: Apnea; Birth Weight; Caffeine; Disease Management; Female; Gestational Age; Humans; Infant; Infant,

2017
Caffeine for apnea in bronchiolitis.
    The Journal of pediatrics, 2017, Volume: 182

    Topics: Apnea; Bronchiolitis; Caffeine; Humans; Infant, Premature; Infant, Premature, Diseases

2017
Use of caffeine for preterm infants in Australia and New Zealand: A survey.
    Journal of paediatrics and child health, 2016, Volume: 52, Issue:12

    Topics: Airway Extubation; Apnea; Caffeine; Health Care Surveys; Humans; Infant, Newborn; New Zealand; Pract

2016
Economics of Home Monitoring for Apnea in Late Preterm Infants.
    Respiratory care, 2017, Volume: 62, Issue:1

    Topics: Ambulatory Care; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Cost Savings; Gest

2017
Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine?
    Journal of neonatal-perinatal medicine, 2016, Volume: 9, Issue:4

    Topics: Apnea; Atrial Premature Complexes; Bradycardia; Caffeine; Central Nervous System Stimulants; Cyclope

2016
A low cost, simplified, and scaleable pneumotachograph and face mask for neonatal mouse respiratory measurements.
    Journal of pharmacological and toxicological methods, 2017, Volume: 86

    Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Equipment Design; Fem

2017
Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats.
    Respiratory physiology & neurobiology, 2017, Volume: 240

    Topics: Analysis of Variance; Anesthetics; Animals; Animals, Newborn; Apnea; Caffeine; Carbon Dioxide; Centr

2017
Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone.
    Respiratory physiology & neurobiology, 2009, Feb-28, Volume: 165, Issue:2-3

    Topics: Age Factors; Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Hypoxia;

2009
Acute hemodynamic effects of caffeine administration in premature infants.
    Journal of perinatology : official journal of the California Perinatal Association, 2009, Volume: 29, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Hemodynamics; Humans; Infant, Newborn;

2009
Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia.
    Pediatric research, 2010, Volume: 68, Issue:2

    Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Hypox

2010
Orphan drugs. Viridian Pharma replies.
    BMJ (Clinical research ed.), 2010, Dec-07, Volume: 341

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Drug Costs; Humans; Infant, Newborn; Orphan Drug

2010
Economic evaluation of caffeine for apnea of prematurity.
    Pediatrics, 2011, Volume: 127, Issue:1

    Topics: Apnea; Caffeine; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Infant, Premature, Diseases

2011
Archimedes: Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
    Archives of disease in childhood, 2011, Volume: 96, Issue:8

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb

2011
Alteration of carotid body chemoreflexes after neonatal intermittent hypoxia and caffeine treatment in rat pups.
    Respiratory physiology & neurobiology, 2011, Aug-15, Volume: 177, Issue:3

    Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Apnea; Body Temperature; Body Weight;

2011
What are the main research findings during the last 5 years that have changed my approach to clinical practice?
    Archives of disease in childhood. Fetal and neonatal edition, 2013, Volume: 98, Issue:1

    Topics: Apnea; Caffeine; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant, Extremely Premature;

2013
Neuroprotection for premature infants?: another perspective on caffeine.
    JAMA, 2012, Jan-18, Volume: 307, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Female; Humans; Infant, Pre

2012
Caffeine therapy in neonatal intensive care.
    Irish medical journal, 2012, Volume: 105, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Child, Preschool; Humans; Inf

2012
Caffeine as treatment for bronchiolitis-related apnoea.
    Journal of paediatrics and child health, 2012, Volume: 48, Issue:7

    Topics: Apnea; Bronchiolitis; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur

2012
Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:3

    Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Agents; Dried Blood Spot Testing; Female; Gest

2013
Effects of caffeine and/or nasal CPAP treatment on laryngeal chemoreflexes in preterm lambs.
    Journal of applied physiology (Bethesda, Md. : 1985), 2013, Mar-01, Volume: 114, Issue:5

    Topics: Animals; Animals, Newborn; Apnea; Arterial Pressure; Bradycardia; Caffeine; Continuous Positive Airw

2013
Influence of age, body temperature, GABAA receptor inhibition and caffeine on the Hering-Breuer inflation reflex in unanesthetized rat pups.
    Respiratory physiology & neurobiology, 2013, Mar-01, Volume: 186, Issue:1

    Topics: Aging; Animals; Animals, Newborn; Apnea; Body Temperature; Caffeine; Central Nervous System Stimulan

2013
[IS SUBARACHNOID ADMINISTRATION OF CAFFEINE IN APNEA DURING HIGH SPINAL ANESTHESIA?].
    Khirurgiia, 1963, Volume: 39

    Topics: Anesthesia; Anesthesia, Spinal; Anesthesiology; Apnea; Caffeine; Humans

1963
[PRINCIPAL HAZARDS OF SPINAL ANESTHESIA AND METHODS FOR THEIR ELIMINATION].
    Vestnik khirurgii imeni I. I. Grekova, 1963, Volume: 91

    Topics: Adjuvants, Anesthesia; Anesthesia; Anesthesia, Spinal; Anesthesiology; Apnea; Blood Pressure; Blood

1963
Apnoeas in bronchiolitis: is there a role for caffeine?
    Archives of disease in childhood, 2005, Volume: 90, Issue:4

    Topics: Apnea; Bronchiolitis; Caffeine; Central Nervous System Stimulants; Humans; Infant

2005
Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats.
    Pediatric research, 2006, Volume: 59, Issue:4 Pt 1

    Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Hyper

2006
Caffeine for apnea of prematurity.
    The New England journal of medicine, 2006, May-18, Volume: 354, Issue:20

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb

2006
Correlation between plasma and urinary caffeine levels in preterm infants.
    Journal of perinatal medicine, 2006, Volume: 34, Issue:4

    Topics: Apnea; Caffeine; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Male

2006
[Caffeine citrate utilization for treatment of apnea in French neonatal units].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:10

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Drug

2006
[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:10

    Topics: Ambulatory Care; Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Continu

2006
Caffeine for apnea of prematurity.
    The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Diuresis; Growth; Humans; Infant, Low Birth Weig

2006
Caffeine for apnea of prematurity.
    The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9

    Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, P

2006
Serum caffeine concentrations in preterm neonates.
    American journal of perinatology, 2007, Volume: 24, Issue:1

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cross-Sectional Studies; Female; Gestational Age

2007
Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?
    Pediatrics, 2007, Volume: 119, Issue:5

    Topics: Apnea; Caffeine; Citrates; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature

2007
On the caffeination of prematurity.
    The New England journal of medicine, 2007, Nov-08, Volume: 357, Issue:19

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb

2007
Use of caffeine in neonates.
    American journal of hospital pharmacy, 1984, Volume: 41, Issue:8

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases

1984
Ontogeny of human caffeine and theophylline metabolism.
    Developmental pharmacology and therapeutics, 1984, Volume: 7 Suppl 1

    Topics: Adult; Aged; Apnea; Caffeine; Child; Child, Preschool; Half-Life; Humans; Infant; Infant, Newborn; I

1984
Maternal coffee drinking and unusually high concentrations of caffeine in the newborn.
    Journal of toxicology. Clinical toxicology, 1984, Volume: 22, Issue:5

    Topics: Apnea; Caffeine; Coffee; Female; Half-Life; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange;

1984
Effect of caffeine on control of breathing in infantile apnea.
    The Journal of pediatrics, 1983, Volume: 103, Issue:6

    Topics: Apnea; Caffeine; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Maximal Voluntary Ventil

1983
T4 levels in methylxanthine-treated premature newborns.
    Pediatric pharmacology (New York, N.Y.), 1983, Volume: 3, Issue:3-4

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Theoph

1983
Interaction of caffeine and continuous distending airway pressure in neonatal apnea.
    American journal of perinatology, 1983, Volume: 1, Issue:1

    Topics: Apnea; Caffeine; Combined Modality Therapy; Humans; Infant, Newborn; Infant, Premature, Diseases; Lu

1983
Effects of caffeine in the treatment of apnea.
    Canadian Medical Association journal, 1984, Apr-15, Volume: 130, Issue:8

    Topics: Animals; Apnea; Caffeine; Cerebrovascular Circulation; Coronary Circulation; Humans; Infant, Newborn

1984
The metabolic effects of caffeine in the newborn infant.
    Pediatric pharmacology (New York, N.Y.), 1981, Volume: 1, Issue:3

    Topics: Apnea; Blood Glucose; Caffeine; Catecholamines; Electrolytes; Heart Rate; Homeostasis; Humans; Infan

1981
Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
    European journal of clinical pharmacology, 1983, Volume: 24, Issue:3

    Topics: Apnea; Caffeine; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline

1983
Plasma xanthine levels in premature infants treated for apnoea with theophylline.
    Journal of clinical and hospital pharmacy, 1983, Volume: 8, Issue:2

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Xanth

1983
Apnea associated with theophylline withdrawal in a term neonate.
    American journal of diseases of children (1960), 1982, Volume: 136, Issue:1

    Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exchange

1982
Pharmacokinetic aspects of caffeine in premature infants with apnoea.
    European journal of clinical pharmacology, 1982, Volume: 22, Issue:1

    Topics: Apnea; Caffeine; Female; Half-Life; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Ki

1982
Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates.
    Developmental pharmacology and therapeutics, 1982, Volume: 4, Issue:1-2

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Saliva; Theophylline; Xanthin

1982
[Use of caffeine in the treatment of apnea in premature infants].
    Developmental pharmacology and therapeutics, 1982, Volume: 4 Suppl

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Time

1982
Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline.
    Medical hypotheses, 1982, Volume: 9, Issue:6

    Topics: Apnea; Caffeine; Electrocardiography; False Negative Reactions; Humans; Infant, Newborn; Infant, New

1982
Caffeine and theophylline: serum/CSF correlation in premature infants.
    The Journal of pediatrics, 1980, Volume: 96, Issue:6

    Topics: Apnea; Blood-Brain Barrier; Caffeine; Chromatography, Liquid; Humans; Infant, Newborn; Infant, Prema

1980
Pharmacologic considerations in the therapy of neonatal apnea.
    Pediatric clinics of North America, 1981, Volume: 28, Issue:1

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Monitoring, Physiologic; Theoph

1981
Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea.
    Seminars in perinatology, 1981, Volume: 5, Issue:4

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Re

1981
Methylxanthines in serum, saliva, and spinal fluid of premature infants.
    Seminars in perinatology, 1981, Volume: 5, Issue:4

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Sa

1981
Adverse effects of caffeine and theophylline in the newborn infant.
    Seminars in perinatology, 1981, Volume: 5, Issue:4

    Topics: Apnea; Asphyxia Neonatorum; Caffeine; Cardiovascular System; Central Nervous System; Digestive Syste

1981
[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1981, Volume: 129, Issue:12

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Protein Binding; Th

1981
Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
    The Journal of pediatrics, 1980, Volume: 96, Issue:3 Pt 1

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Regression Analysis; Saliva;

1980
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
    Journal of chromatography, 1980, Nov-14, Volume: 221, Issue:1

    Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant,

1980
Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity.
    Clinical and investigative medicine. Medecine clinique et experimentale, 1993, Volume: 16, Issue:3

    Topics: Apnea; beta-Endorphin; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthine; Xan

1993
Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach.
    Journal of paediatrics and child health, 1993, Volume: 29, Issue:2

    Topics: Aminophylline; Apnea; Caffeine; Electric Impedance; Female; Humans; Infant, Newborn; Infant, Prematu

1993
Aminophylline versus caffeine citrate...
    Acta paediatrica (Oslo, Norway : 1992), 1995, Volume: 84, Issue:10

    Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Cardiotonic Agents; Citrates; Clinical Trials as Topic;

1995
Apnea following spinal anaesthesia in two former pre-term infants.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1998, Volume: 45, Issue:10

    Topics: Age Factors; Anesthesia, Spinal; Anesthetics, Local; Apnea; Benzoates; Bradycardia; Caffeine; Centra

1998
The effect of theophylline on apnoea and hypoxaemic episodes in the premature neonate during the 1st 3 days after birth.
    Annals of tropical paediatrics, 1998, Volume: 18, Issue:3

    Topics: Apnea; Blood Pressure; Bradycardia; Bronchodilator Agents; Caffeine; Female; Gestational Age; Humans

1998
Caffeine overdose in a premature infant: clinical course and pharmacokinetics.
    Anaesthesia and intensive care, 1999, Volume: 27, Issue:3

    Topics: Age Factors; Apnea; Caffeine; Central Nervous System Stimulants; Drug Overdose; Female; Humans; Infa

1999
Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants.
    Southern medical journal, 2000, Volume: 93, Issue:3

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Critical Care; Data Interpretation, Statistical;

2000
Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity.
    Journal of perinatology : official journal of the California Perinatal Association, 2000, Volume: 20, Issue:2

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature; Infant, Pr

2000
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
    Research communications in molecular pathology and pharmacology, 1999, Volume: 105, Issue:1-2

    Topics: Aminophylline; Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf

1999
Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea.
    Pediatrics, 2001, Volume: 107, Issue:4

    Topics: Apnea; Body Weight; Caffeine; Energy Metabolism; Humans; Infant, Newborn; Infant, Premature, Disease

2001
Postoperative recovery after inguinal herniotomy in ex-premature infants and the use of caffeine.
    British journal of anaesthesia, 2002, Volume: 88, Issue:2

    Topics: Apnea; Caffeine; Central Nervous System Stimulants; Hernia, Inguinal; Humans; Infant; Infant, Newbor

2002
Caffeine in apnoeic Asian neonates: a sparse data analysis.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:1

    Topics: Apnea; Asia; Body Weight; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure

2002
Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.
    The Journal of pediatrics, 1977, Volume: 90, Issue:3

    Topics: Apnea; Caffeine; Carbon Dioxide; Drug Evaluation; Humans; Hydrogen-Ion Concentration; Infant, Low Bi

1977
Biotransformation of theophylline to caffeine in premature newborn.
    Lancet (London, England), 1978, Dec-02, Volume: 2, Issue:8101

    Topics: Administration, Oral; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature

1978
Methylation of theophylline to caffeine in premature infants.
    Lancet (London, England), 1979, Apr-14, Volume: 1, Issue:8120

    Topics: Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Methylatio

1979
Sequelae of caffeine treatment in preterm infants with apnea.
    The Journal of pediatrics, 1979, Volume: 94, Issue:1

    Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf

1979
Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
    The Journal of pediatrics, 1979, Volume: 94, Issue:4

    Topics: Administration, Oral; Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseas

1979
Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.
    Archives of disease in childhood, 1979, Volume: 54, Issue:3

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Mil

1979
Interconversion of theophylline and caffeine in newborn infants.
    The Journal of pediatrics, 1979, Volume: 94, Issue:6

    Topics: Age Factors; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Disease

1979
Metabolism of theophylline to caffeine in premature newborn infants.
    The Journal of pediatrics, 1979, Volume: 94, Issue:6

    Topics: Adult; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; The

1979
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant.
    The Journal of pediatrics, 1979, Volume: 94, Issue:6

    Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophyl

1979
Relationship of plasma and CSF concentrations of caffeine in neonates with apnea.
    The Journal of pediatrics, 1979, Volume: 95, Issue:4

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases

1979
Metabolism of theophylline to caffeine in human fetal liver.
    Science (New York, N.Y.), 1979, Dec-14, Volume: 206, Issue:4424

    Topics: Apnea; Biotransformation; Caffeine; Cells, Cultured; Gestational Age; Humans; Infant, Newborn; Liver

1979
Apneic spells and transcutaneous PO2: treatment with caffeine, 19-year follow-up.
    Birth defects original article series, 1979, Volume: 15, Issue:4

    Topics: Apnea; Blood Gas Analysis; Blood Pressure; Caffeine; Diagnosis, Differential; Follow-Up Studies; Hea

1979
Micro-method for the determination of caffeine and theophylline allowing direct application of biological fluids to thin-layer chromatography plates.
    Journal of chromatography, 1978, Jul-01, Volume: 146, Issue:1

    Topics: Apnea; Caffeine; Child; Child, Preschool; Chromatography, Thin Layer; Female; Humans; Infant; Infant

1978
The xanthine treatment of apnea of prematurity.
    Pediatrics, 1975, Volume: 55, Issue:5

    Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Di

1975
[Effects of coffee on the respiratory system].
    Revue des maladies respiratoires, 1992, Volume: 9, Issue:6

    Topics: Adult; Apnea; Bronchial Neoplasms; Caffeine; Coffee; Female; Humans; Infant, Newborn; Infant, Newbor

1992
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants.
    Therapeutic drug monitoring, 1992, Volume: 14, Issue:1

    Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Caffeine; Humans; Infant, Newborn; Infa

1992
Severe caffeine intoxication in a preterm neonate.
    European journal of pediatrics, 1992, Volume: 151, Issue:6

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male

1992
Percutaneous caffeine application in the treatment of neonatal apnoea.
    European journal of pediatrics, 1991, Volume: 150, Issue:8

    Topics: Administration, Cutaneous; Apnea; Caffeine; Chromatography, High Pressure Liquid; Citrates; Drug Com

1991
[Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea].
    Anales espanoles de pediatria, 1991, Volume: 34, Issue:4

    Topics: Apnea; Asphyxia Neonatorum; Caffeine; Humans; Infant, Newborn; Monitoring, Physiologic; Theophylline

1991
[Caffeine in the treatment of apnea in premature infants].
    Archives francaises de pediatrie, 1990, Volume: 47, Issue:10

    Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases

1990
[Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant].
    Archives francaises de pediatrie, 1990, Volume: 47, Issue:3

    Topics: Administration, Cutaneous; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Ma

1990
Cardiovascular effects of caffeine therapy in preterm infants.
    American journal of diseases of children (1960), 1990, Volume: 144, Issue:10

    Topics: Apnea; Blood Pressure; Caffeine; Cardiac Output; Heart; Heart Rate; Humans; Infant, Newborn; Infant,

1990
Does caffeine affect cerebral blood flow in the preterm infant?
    Acta paediatrica Scandinavica, 1989, Volume: 78, Issue:2

    Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Caffeine; Cerebrovascular Circulation; Humans; Infant;

1989
Caffeine citrate in the NICU.
    Neonatal network : NN, 1989, Volume: 7, Issue:5

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases;

1989
Caffeine citrate. Pointers in practical pharmacology.
    Neonatal network : NN, 1989, Volume: 7, Issue:6

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases

1989
Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication.
    Pediatric pulmonology, 1989, Volume: 7, Issue:2

    Topics: Apnea; Bradycardia; Caffeine; Cheyne-Stokes Respiration; Chromatography, High Pressure Liquid; Femal

1989
Low-dose doxapram for apnoea of prematurity.
    Lancet (London, England), 1986, Apr-05, Volume: 1, Issue:8484

    Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di

1986
Oral versus intramuscular loading of caffeine in idiopathic apnoea of prematurity.
    European journal of pediatrics, 1988, Volume: 148, Issue:3

    Topics: Administration, Oral; Apnea; Blood Glucose; Caffeine; Humans; Infant, Newborn; Infant, Premature, Di

1988
Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test.
    Pediatric research, 1988, Volume: 23, Issue:6

    Topics: Apnea; Breath Tests; Caffeine; Carbon Dioxide; Chromatography, High Pressure Liquid; Gestational Age

1988
Change of plasma half-life of caffeine during caffeine therapy for apnea in premature infants.
    Acta paediatrica Japonica : Overseas edition, 1987, Volume: 29, Issue:4

    Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature

1987
Developmental changes of caffeine elimination in infancy.
    Developmental pharmacology and therapeutics, 1988, Volume: 11, Issue:5

    Topics: Aging; Apnea; Caffeine; Drug Administration Schedule; Gestational Age; Half-Life; Humans; Infant; In

1988
The relationship between theophylline, caffeine and heart rate in neonates.
    Annals of clinical biochemistry, 1988, Volume: 25 ( Pt 4)

    Topics: Aminophylline; Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Theophylline

1988
Maturation of caffeine metabolic pathways in infancy.
    Clinical pharmacology and therapeutics, 1988, Volume: 44, Issue:2

    Topics: Acetylation; Administration, Oral; Adult; Age Factors; Apnea; Caffeine; Chromatography, High Pressur

1988
Apnea in infancy: pathophysiology, diagnosis, and treatment.
    New York state journal of medicine, 1986, Volume: 86, Issue:2

    Topics: Aminophylline; Apnea; Caffeine; Chemoreceptor Cells; Home Nursing; Humans; Infant; Infant, Newborn;

1986
Simultaneous administration of caffeine and phenobarbitone in infants with apnea.
    The Journal of pediatrics, 1987, Volume: 110, Issue:4

    Topics: Apnea; Caffeine; Drug Therapy, Combination; Half-Life; Humans; Infant; Infant, Newborn; Infant, Prem

1987
[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux].
    Archives francaises de pediatrie, 1987, Volume: 44, Issue:5

    Topics: Apnea; Caffeine; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature, Diseases; Xant

1987
Infant apnea.
    Pediatric clinics of North America, 1986, Volume: 33, Issue:3

    Topics: Airway Obstruction; Apnea; Bradycardia; Caffeine; Cardiography, Impedance; Home Nursing; Humans; Inf

1986
Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study.
    Pediatrics, 1986, Volume: 78, Issue:1

    Topics: Apnea; Birth Weight; Caffeine; Female; Humans; Infant, Newborn; Maternal Age; Pregnancy; Prenatal Ex

1986
Apnoea and seizures.
    Archives of disease in childhood, 1986, Volume: 61, Issue:8

    Topics: Apnea; Caffeine; Electroencephalography; Female; Humans; Infant; Male; Seizures

1986
Effect of caffeine on pneumogram and apnoea of infancy.
    Archives of disease in childhood, 1986, Volume: 61, Issue:9

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases;

1986
[Peculiarities of drug therapy in childhood].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1986, Volume: 134, Issue:11

    Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone;

1986
Delay in caffeine elimination in breast-fed infants.
    Pediatrics, 1987, Volume: 79, Issue:2

    Topics: Apnea; Biological Availability; Bottle Feeding; Breast Feeding; Caffeine; Fatty Acids, Nonesterified

1987
Caffeine citrate: an alternative to theophylline for apnea in prematurity.
    Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:10

    Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Theophylline

1985
Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding.
    Pediatrics, 1985, Volume: 76, Issue:5

    Topics: Aging; Apnea; Breast Feeding; Caffeine; Cholestasis; Citrates; Drug Combinations; Gestational Age; H

1985
[Resuscitation of the newborn].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1969, Jun-08, Volume: 45, Issue:27

    Topics: Acidosis, Respiratory; Apnea; Bicarbonates; Caffeine; Catheterization; Cyanosis; Equipment and Suppl

1969
[Apnea periods in the premature infant].
    Tijdschrift voor ziekenverpleging, 1974, Aug-27, Volume: 27, Issue:31

    Topics: Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physi

1974